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Applications of nanoscale metal–organic
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Nanoscale metal–organic frameworks (NMOFs) are an interesting and unique class of hybrid porous
materials constructed by the self-assembly of metal ions/clusters with organic linkers. The high storage
capacities, facile synthesis, easy surface functionalization, diverse compositions and excellent
biocompatibilities of NMOFs have made them promising agents for theranostic applications. By
combination of a large variety of metal ions and organic ligands, and incorporation of desired molecular
functionalities including imaging modalities and therapeutic molecules, diverse MOF structures with
versatile functionalities can be obtained and utilized in biomedical imaging and drug delivery. In recent
years, NMOFs have attracted great interest as imaging agents in optical imaging (OI), magnetic
resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET) and
photoacoustic imaging (PAI). Furthermore, the significant porosity of MOFs allows them to be loaded
with multiple imaging agents and therapeutics simultaneously and applied for multimodal imaging and
therapy as a single entity. In this review, which is intended as an introduction to the use of MOFs in
biomedical imaging for a reader entering the subject, we summarize the up-to-date progress of NMOFs
as bioimaging agents, giving (i) a broad perspective of the varying imaging techniques that MOFs can
enable, (ii) the different routes to manufacturing functionalised MOF nanoparticles and hybrids, and (iii)
the integration of imaging with differing therapeutic techniques. The current challenges and
perspectives of NMOFs for their further clinical translation are also highlighted and discussed.
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1. Introduction
Porous materials are increasingly becoming attractive in bio-
medical applications due to their excellent intrinsic properties,
such as large tunable porosities and fine control of chemical
composition.1 Metal–organic frameworks (MOFs), which are
also known as porous coordination polymers or porous coordination
networks, are a class of porous hybrid solids that are formed by
the self-assembly of metal ions or metal ion clusters and
organic polydentate bridging linkers.2,3 Owing to their structural
and functional tunability, much effort has been made to develop
MOFs, particularly nanoscale metal–organic frameworks (NMOFs),
over the past two decades to apply them in many areas, including
but not limited to gas separation, gas storage,4,5 catalysis,6,7 non-
linear optics,8,9 chemical sensing,10–12 drug delivery13–15 and
imaging.16–20
NMOFs exhibit various characteristics that make them ideal
materials for biomedical applications. Their highly porous
structures and versatile functionality allow accommodation of
high loadings of therapeutic and imaging agents and their
controlled release, as well as protection against enzymatic
degradation and self-quenching in living systems.21–24
Compared with conventional nanomaterials such as inorganic
zeolites, mesoporous silica, quantum dots, metal nano-
particles, and organic nanocarriers of lipids or polymers,
NMOFs typically possess a larger cargo loading capacity, good
biocompatibility and ease of functionalisation.25 In the longer
term, NMOFs are also intrinsically biodegradable as a result of
their relatively labile metal–ligand bonds.26 The effectively
infinite combination of metal clusters and organic linkers
contributes to their compositional and structural tunability
and allows the production of NMOFs with various pore sizes
ranging from micropores to macropores, rigid or flexible
skeletons, and diverse surface chemistries.27 Furthermore,
their mild synthetic conditions enable the design of numerous
NMOFs and incorporation of a large variety of molecular
functionalities on their inner and outer surfaces, including
imaging modalities, therapeutics and targeting ligands.
Since Lin and co-workers first reported the design of NMOFs as
potential multimodal contrast enhancing agents for biomedical
imaging in 2006,28 an increasing number of studies have used
them as imaging agents for optical imaging (OI), magnetic
resonance imaging (MRI), computed tomography (CT), positron
emission tomography (PET) and photoacoustic imaging
(PAI).18,28–37 NMOFs offer a potential new class of imaging agents
combining the characteristics of both inorganic and organic
nanomaterials; the ease of construction of structures with metal
ions/clusters or linkers with imaging abilities, or their doping with
imaging molecules, makes them highly promising candidates. In
comparison to existing imaging agents, NMOFs can offer high
loading capacities for cargo molecules, high protection against
enzymatic degradation, minimal release in the blood, and
efficient delivery to targeted tissues, in contrast to the short
blood circulation times and non-specific biodistributions often
characteristic of conventional imaging agents.38 For example,
NMOF-based MRI contrast agents have shown enhanced
relaxivities compared to commercially available Gd contrast
agents39 and even other Gd nanoparticulate systems,40,41 while
an archetypal Hf MOF showed superior contrast for computed
tomographic imaging compared to an I-based agent, even at a
lower dose, that could be promising in decreasing the radiation
dose to which the patients must be exposed.42 Moreover,
NMOFs can be employed as multimodal imaging agents by the
combination of multiple imaging functionalities in a single entity,
and as image-guided therapy agents by achieving simultaneous
imaging and therapy.43–45
There are four main approaches for the construction of
MOFs containing imaging agents (i) encapsulation of the
agents within the pores of MOFs during the synthesis, (ii) their
incorporation as intrinsic structural components of MOFs, (iii)
immersion of already synthesized MOFs in a solution of
imaging agents and so loading them inside the pores by size
effect, ion-exchange or post-synthetic modification, collectively
known as the post-insertion method, and (iv) attachment of
imaging agents by covalent conjugation, or electrostatic or
hydrophobic interactions, to the surface of MOFs as shown in
Scheme 1.46–49
In this review, we will highlight the preparation and
applications of NMOFs as imaging and theranostic agents in
the biomedical field. Compared to other excellent reviews
related to the applications of MOFs in biomedicine,27,50–52
imaging and sensing,38,48,53,54 or theranostics,55,56 this review
will solely focus on and discuss the bioimaging applications of
NMOFs, exemplifying the different strategies to facilitate
mono- and multimodal imaging with select examples, and
offering insight into the combination of imaging with other
biological applications. This review is not intended to be a
comprehensive overview of the field, but an introduction to the
varying biomedical imaging techniques that MOFs can be
Scheme 1 Main approaches for the construction of MOFs with imaging
capabilities. (a) The in situ encapsulation of imaging agents during
MOF synthesis. (b) Their integration as intrinsic components of the MOF,
either as a linker or metal ion or metal cluster. (c) Postsynthetic loading
of imaging agents into the porosity of the MOF. (d) Postsynthetic
functionalisation of the MOF particle surface with imaging units.
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applied to and a discussion of the varying methodologies to
engender MOFs with imaging functionality.
2. MOFs as monomodal imaging
agents
2.1. Optical imaging
Optical imaging (OI) is an imaging modality that uses light
illumination at visible or near-infrared (NIR) wavelengths,
which can be detected by optical cameras.57 OI provides real-
time visualization of organs, tissues, and cells and monitors the
progression of any morphological and biochemical changes
non-invasively, allowing intraoperative image-guided surgery.
The technique employs neither ionizing radiation, as in computed
tomography, nor radioactive compounds, as in positron emission
tomography, and it is a rapid and suitable imaging mode for
high-throughput screening for both in vitro and in vivo imaging
with non-invasion and high signal sensitivity.17 The basis of the
technique relies on the absorption of the externally applied
photon energy of a certain wavelength by fluorophores, and
then its emission as a new photon with energy in the longer
wavelengths. However, OI has limitations in terms of quantifying
fluorescence intensity in living organisms accurately due to auto-
fluorescence, intrinsic tissue signal attenuation, and the shallow
tissue penetration of light. Therefore, many fluorescent materials
have been investigated to obtain strong optical imaging agents
that can offer deep tissue and intracellular imaging.58
Luminescent MOFs have been utilized as effective optical
imaging agents in the last two decades due to their attractive
properties such as high payloads, tailorable surface chemistry
that provides improved pharmacokinetics, and tunable sizes
and structures.38 Various MOF structures with luminescent
properties for optical biomedical imaging have been developed
by combining MOFs with fluorescent dyes, photosensitizers or
fluorescent drugs,13,18,29,34,59–72 metal ions/clusters (particularly
lanthanides),23,73 or luminescent nanoparticles such as
persistent luminescent nanoparticles (PLNPs),74,75 upconversion
nanoparticles (UCNPs)76–78 or quantum dots (QDs).79
2.1.1. Combination with fluorescent dyes/photosensitizers/
fluorescent drugs. Combining MOFs with fluorescent dyes,
photosensitizers, or fluorescent drugs – particularly anticancer
drugs – by using them as a linker or a cargo molecule is a very
advantageous way to obtain various MOFs that emit in different
ranges of the optical spectrum. This strategy is also very effective
to prevent aggregation-induced quenching and achieve consistent
luminescence features under harsh conditions by the confinement
effect within the pores of MOFs, hence improving the photo-
luminescence performances and efficiencies of the fluorescent
species.46 By using these approaches, various fluorescent dyes,
photosensitizers or fluorescent drugs have been incorporated
into different types of MOFs for the detection of diseases with
high sensitivity, or determination of cellular uptake efficiency of
synthesized MOF systems.18,29,59–63,69,71,72,80
Fluorescent dyes. Liu et al. have reported the synthesis of
phosphorescent MOFs using a phosphorescent ruthenium
complex, [Ru(2,20-bipyridyl-5,50-dicarboxylic acid)(2,20-bipyridine)2],
as bridging ligand, and Zr(IV) or Zn(II) connecting points,
achieving a dye loading of 57.4% and 78.7%, respectively.17
Then, the synthesized nanoparticles were further stabilized
with a silica coating, functionalized with poly(ethylene glycol)
(PEG) and an anisamide targeting molecule which provided a
cancer specific optical imaging of H460 lung cancer cells
in vitro. Furthermore, the results showed that zirconium MOFs
exhibited higher stability in aqueous conditions compared to
zinc MOFs. On the other hand, Ryu et al. size-selectively
encapsulated resorufin and rhodamine-6G within nanocrystal-
line metal–organic frameworks (NMOFs, Fig. 1a), MOF-801,
[Zr6O4(OH)4(fumarate)6]n, also known as Zr-fum, in which the
linker is fumaric acid, and UiO-67, [Zr6O4(OH)4(BPDC)6]n
(BPDC = 4,40-biphenyldicarboxylate, UiO: Universitetet i Oslo),
during their crystal growth and obtained resorufin-in-nMOF-801
(RsCnMOF-801) and rhodamine-6G-in-nUiO-67 (R6GCnUiO-
67). The Zr-MOF nanoparticles showed exceptional stabilities
in biomedical environment, and enhanced photoluminescence
properties, such that they could preserve the fluorescence even
after 9 days.18 The resulting particles were successfully utilized
for reliable and reproducible fluorescence imaging of FL83B
human hepatocyte cells and HepG2 human hepatocellular
carcinoma cells after being functionalized by galactosylation,
to improve the biocompatibility and cellular uptake of MOFs
through the high attachment affinity of galactose residues on the
nanoparticles to the asialoglycoprotein receptors in the plasma
membranes of liver cells (Fig. 1b–e).
In another study, Gao et al. showed encapsulation of rhodamine
b (RhB) within a hierarchical-pore metal–organic framework
(H-MOF), using a one-step approach that was achieved by
assembling MIL-53(Al)-NH2, constructed from [AlO6] octahedral
chains connected by 2-aminobenzene-1,4-dicarboxylate (BDC-NH2)
linkers, with formula [Al(OH)(BDC-NH2)]n and where MIL
stands for Materials of Institute Lavoisier, in an aqueous
solution of RhB, which serves as a fluorescent imaging
agent.29 The obtained red fluorescence emitting H-MOFs were
employed for in vitro imaging of murine gastric cancer 803
(MGC-803) cells and human airway smooth muscle cell
(HASMC), and allowed in vivo imaging of athymic nude mice
with good stability, biocompatibility and high imaging
efficiency, avoiding the interference of autofluorescence.
Furthermore, the as-synthesized fluorescent HMOFs were also
successfully utilized as a nanocarrier by simultaneously loading
the macromolecular drug tetracycline hydrochloride (TCH) and
small molecule anticancer drug 5-fluorouracil (5-FU) with high
loading efficiency, and delivery into cells. Mao and co-workers
reported the fabrication of MOF-based fluorescent probes
self-assembled from Zn(II) and imidazole-2-carboxyaldehyde
(ICA), namely nanoscale ZIF-90 (formula [Zn(ICA)2]n, where
ZIF stands for zeolitic imidazolate framework), to target sub-
cellular mitochondria and visualize mitochondrial adenosine
triphosphate (ATP) in live cells.81 Rhodamine (RhB) was
encapsulated into ZIF-90 during synthesis, which resulted in
its quenching due to the self-quenching effect of RhB (Fig. 2a).
In the presence of ATP, the competitive coordination between
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ATP and the metal node of ZIF-90 led to the decomposition of
RhB/ZIF-90 complex and consequently release and fluorescence
recovery of RhB, and thus mitochondrial ATP imaging in living
cells as shown in Fig. 2b–e.
MOFs were also successfully loaded with 1,3,5,7-tetramethyl-4,
4-difluoro-8-bromomethyl-4-bora-3a,4a-diaza-s-indacene (Br-BODIPY)
fluorescent dye by postsynthetic modification (PSM) of iron-
carboxylate MIL-101(Fe) (trimeric iron(III) octahedral clusters
connected with benzene-1,4-dicarboxylate (BDC) linkers of
formula [Fe3O(BDC)3(H2O)2X]n, where X is a monocounterion
typically OH or Cl) and used as optical imaging contrast
agents for HT-29 human colon adenocarcinoma cells.59 To
increase the stability of the particles and decrease cargo release,
the nanosized MIL-101(Fe) particles were further functionalized
by a silica coating and conjugated with the cisplatin prodrug
(ethoxysuccinato-cisplatin, ESCP) for anticancer therapy. The
cytotoxicity studies showed efficient cancer cell killing with the
ESCP loaded nanoparticles, but slightly less cytotoxicity than
free cisplatin. The functionalization of nanoparticles with a
cancer targeting peptide, c(RGDfK), which has high binding
affinity toward avb3 integrin overexpressed on cancer cells,
slightly improved the cytotoxic effect of the nanoparticles
providing similar IC50 (the half maximal inhibitory concentration)
to that of free cisplatin. Such materials that combine imaging and
drug delivery are often termed theranostics, for which MOFs are
highly suited.55,56
Similarly, Wuttke et al. reported the encapsulation of fluorescein
dye in lipid-coated MOF nanoparticles and their successful cellular
uptake.60 In the study, the mesoporous iron(III) carboxylate
MIL-100(Fe), which is constructed from octahedral trimers
connected by benzene-1,3,5-tricarboxylate (BTC) to give formula
[Fe3O(BTC)2(H2O)2X]n with large pore (diameter 2.4–2.9 nm) and
window sizes (0.6–0.9 nm), and the mesoporous chromium(III)
analogue MIL-101(Cr) with large pore (diameter 2.9–3.4 nm) and
window sizes (1.2–1.7 nm), were loaded with fluorescein dye. The
dye-loaded MOF nanoparticles were subsequently encapsulated by
the formation of a bilayer of lipid DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine) through a controlled solvent-exchange deposition
of the lipid molecules onto the MOF surface. The MOF@lipid
nanoparticles synergistically combined the properties of liposomes
and porous particles, storing the dye molecules inside the MOF
pores while the lipid coating prevented the premature release of the
dye and improved the colloidal stability of the nanoparticles.
In vitro fluorescence microscopy studies showed high accumulation
of the fluorescein-loaded nanoparticles with strong emission in T24
human bladder carcinoma cells.
The well-known low-toxic luminescent organic dye calcein
(cal) has often been employed as a model drug in order to
determine the cell internalization and drug delivery potential of
MOF nanoparticles.69,82–84 Calcein is a hydrophilic fluorophore
that is unable to cross cell membranes in significant quantities;
rather the fluorescent molecule needs a drug delivery system
(DDS) to facilitate its transport. In addition, calcein has a self-
quenching nature at high concentrations that makes the vesicles
carrying high local concentrations of calcein undetectable by
fluorescent microscopy. However, upon its release from the
carriers and dilution in the cytoplasmic environment, the green
fluorescence of calcein can be detected by fluorescence-based
techniques.85 Calcein was postsynthetically incorporated into
Zr-based MOFs of the UiO topology by Orellana-Tavra et al. to
study the endocytosis mechanism of Zr-MOFs through linker
functionalization (Fig. 3a).64 In the study, UiO-66 topology MOFs
with general formula [Zr6O4(OH)4(BDC)6]n were prepared with
different particle sizes and different surface chemistries by
substituting the original BDC linker with functionalized or
Fig. 1 (a) Scheme for the encapsulation of resorufin and rhodamine-6G
within NMOFs to produce RsCnMOF-801 and R6GCnUiO-67,
respectively. Confocal laser scanning microscopic images of (b) and (c)
FL83B cells, and (d) and (e) HepG2 cells, after treatment with (b) and
(d) galactosylated RsCnMOF-801, and (c) and (e) galactosylated R6GC
nUiO-67. Reproduced with permission.18 Copyright (2017) American
Chemical Society.
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extended linkers, and subsequently loaded with calcein. Fig. 3b
schematizes the linkers (L1–L6) used in the study to build the
Zr-based MOFs termed as Zr-L1 to Zr-L6, where L1 is BDC; L2–L4
are BDC functionalized with –Br, –NO2, and –NH2, respectively;
L5 and L6 are extended linkers naphthalene-2,6-dicarboxylic acid
(NDC) and BPDC, respectively. While the particle size does not
significantly affect the cellular uptake mechanism in HeLa cells,
visualised by intracellular calcein, control of surface chemistry
through linker functionalization has a great influence. After 2 h
incubation, a high degree of cal@Zr-L2, cal@Zr-L3 and cal@
Zr-L4 were localized in cells as seen in Fig. 3c. The endocytosis
mechanism can also be probed by the use of selected pharma-
cological endocytosis inhibitors, which demonstrated
minimal particle size effects on uptake of cal@Zr-L1 (Fig. 3d),
but also that cal@Zr-L1 (unfunctionalized) and cal@Zr-L3 (–NO2
functionalized) are taken up mostly through clathrin-mediated
endocytosis, while cal@Zr-L5 and cal@Zr-L6 are taken up by the
caveolae-mediated route, and so may avoid lysosomal degradation,
although their total uptake is less than the others (Fig. 3e).
In another study, Haddad et al. utilized calcein to track the
mitochondria targeting efficiencies of UiO-66 nanoparticles
loaded with the anticancer drug dichloroacetate (DCA) and
functionalized with a triphenylphosphonium (TPP) targeting
unit,69 which is a lipophilic cation that accumulates in mito-
chondria as a consequence of the mitochondrial membrane
potential in living cells.65 They reported that MCF-7 human
breast cancer cells treated with the targeted MOF system,
cal-TPP@(DCA5-UiO-66) demonstrated changes in mitochondrial
morphology from elongated and reticular networks (untreated
cells, Fig. 4, left) to short, balloon-shaped, fragmented mito-
chondria (Fig. 4, right) as a result of the DCA toxicity, as observed
by structured illumination microscopy. This effect was less active
with non-targeted cal@(DCA5-UiO-66) which showed still partially
stringy and reticular morphology, as shown by the white arrows in
Fig. 4 (centre). The presence of the MOF in the cells could be
ascertained by the green fluorescence of the calcein.
Photosensitisers. The integration of photosensitizers such as
porphyrins, chlorins or indocyanine green (ICG) into MOFs is
another approach to obtain MOFs with optical imaging capability.
This class of MOFs, named photosensitizer-based MOFs, can act
as multifunctional nanoplatforms combining both photothermal
imaging and photodynamic therapy (PDT) characteristics.
Particularly, porphyrins and their analogues have been widely
investigated due to their unique optoelectronic properties and
versatility.71,72,80 Furthermore, the integration of porphyrins into
MOF structures prevents their easy aggregation and quenching – a
consequence of their large hydrophobic planar structures – and
retains their optoelectronic properties.45
To obtain porphyrin-based MOFs, two different approaches
have primarily been conducted. In the first approach, which
results in porphyrin@MOFs, porphyrins are integrated within
MOFs as guest molecules through encapsulation into the pores
or adsorption on the surface via non-covalent interactions such
Fig. 2 (a) Schematic illustration for the synthesis of RhB/ZIF-90 and host–guest chemistry for fluorescent ATP sensing and mitochondrial ATP imaging in
living cells. Confocal laser scanning microscopy images of HeLa cells incubated with (b) RhB/ZIF-90 nanocrystals for 2 h (lex = 559 nm; lem = 570–
670 nm), and (c) rhodamine 123 for 15 min (lex = 488 nm; lem = 500–545 nm). (d) Bright-field image of HeLa cells, and (e) overlay of images (b)–(d).
Scale bars represent 20 mm. Reproduced with permission.81 Copyright (2017) American Chemical Society.
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as van der Waals forces, p–p stacking, or electrostatic interactions,
or conjugation through covalent or coordinative bonds.86,87
The second approach uses porphyrins as organic linkers due to
their macromolecular heterocyclic structures which can easily be
functionalised with groups capable of coordination with metal
ions or clusters. This class of MOFs is typically characterized by
high porosities that allow accommodation of multiple functional
units. Mostly, carboxylate-functionalised porphyrins such as
5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin (TCPP) are used as
linkers and coordinated with metals to form porphyrinic MOFs.
The divalent metal ions such as Zn, Cu, Co and Cd typically
coordinate to TCPP to produce 2D MOFs, while tri-and tetravalent
Zr, Fe, Hf or Mn metal ions usually form porphyrinic MOFs with
3D structures.87–90 For example, Liu et al. have reported the
construction of biocompatible nanoscale zirconium–porphyrin
metal–organic framework (NPMOF)-based imaging-guided
therapy systems by using a microemulsion strategy and
tuning the reaction conditions carefully.71 The NPMOFs were
synthesized via a microemulsion template and the auxiliary ligand
method using ZrCl4 metal precursor and 5,10,15,20-tetrakis
(4-carboxyl)-21H,23H-porphine (TCPP) ligand as well as benzoic
acid as the auxiliary ligand, PEG-6000 as capping agent, and
Fig. 3 (a) Schematic illustration of different endocytosis mechanisms of Zr-based MOFs. (b) Chemical structures of linkers used to synthesize the
Zr-MOFs. (c) Confocal microscopy images of HeLa cells treated with calcein incorporated Zr-based MOFs for 2 h (green fluorescence indicates calcein,
red shows lysosome marker LysoTracker-Deep red). Effects of pharmacological endocytosis inhibitors on the uptake of (d) Zr-L1 with different particles
sizes, and (e) linker functionalized Zr-based MOFs, as measured by flow cytometry tracking calcein fluorescence. Reproduced with permission.64
Copyright (2017) American Chemical Society.
Fig. 4 Structured illumination microscopy images of untreated (left), cal@(DCA5-UiO-66) treated (centre), and cal-TPP@(DCA5-UiO-66) (right) treated
MCF-7 cells 8 h after incubation. Red fluorescence indicates mitochondria stained with a red fluorescent protein (RFP), blue corresponds to nuclei
stained with DRAQ-5t, and green shows MOFs loaded with calcein. White arrows indicate stringy mitochondria. Reproduced with permission.69
Copyright (2020) American Chemical Society.
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cetyltrimethylammonium bromide (CTAB) as surfactant, in DMF
at 120 1C for 24 h that resulted in spindle-like particles. The
further incubation of the reaction solution under these conditions
caused the formation of bulk zirconium–porphyrin metal–organic
frameworks with a rod-like shape after 40 h, maintaining the
crystal structure of NPMOFs. The obtained MOFs exhibited
efficient fluorescent imaging and PDT by achieving high
porphyrin loading (59.8%), and high chemotherapy efficacy in
tumour tissues through high doxorubicin loading (109% w/w).
Porphyrinic MOFs can also be combined with other functional
nanoparticles due to their porosity, to form multifunctional
compositions. For example, Zeng et al. showed the fabrication
of core–shell gold nanorod@porphyrinic MOFs as multifunctional
theranostic nanoparticles for combined photodynamic/
photothermal/chemotherapy of tumour.80 The core–shell nano-
composites (Fig. 5a and b) were prepared by the growth of a
porphyrinic Zr-MOF, composed of 6-connected Zr6 clusters and
TCPP with the formula [Zr6O4(OH)4(H2O)6(OH)6(TCPP)1.5]n, on the
surface of functionalized gold nanorods (AuNRs), which acted as
seed crystal in the synthesis, and loaded with camptothecin (CPT)
anticancer drug for chemotherapy of tumour. The as-synthesized
AuNR@MOFs@CPT demonstrated high accumulation in the
tumour tissues, exhibiting strong fluorescence intensity arising
from porphyrinic MOFs (Fig. 5c–g), and high photothermal
activity of AuNRs, evident in the photothermal images of 4T1
tumour-bearing mice irradiated with 808 nm laser after 24 h
intravenous injection of AuNR@MOFs@CPT (Fig. 5h and i),
therefore achieving high synergistic efficiency of photodynamic,
photothermal and chemo-therapies in the tumour.
Ju and co-workers showed a different approach for fluorescence
cell imaging using photosensitizers.91 The amino-functionalized
iron(III) carboxylate MOF, MIL-101(Fe)-NH2 (a derivative of
MIL-101(Fe) where the linker is BDC-NH2), was loaded with
camptothecin through non-covalent encapsulation, and
subsequently functionalized with a folic acid cancer targeting
moiety and chlorin e6 (Ce6)-labelled cathepsin B (CaB) substrate
peptide to act as the recognition unit, photosensitizer, and signal
switch. CaB is a lysosomal cysteine endopeptidase overexpressed
in many types of cancer cells. To target CaB and monitor the
targeting effect, a CaB-substrate was conjugated with a Ce6
photosensitizer, which resulted in quenching of Ce6 due to the
electron transfer from the excited Ce6 to MOFs. Upon incubation
of the nanoparticles in cancer cells, Ce6 was released from the
CaB-substrate by the cleavage of the substrate via intracellular
CaB, and its fluorescence intensity was recovered, providing
fluorescence imaging of the cancer cells. In addition to
CaB-activatable fluorescence imaging, the nanoparticles
demonstrated a significant tumour killing effect by synergistic
chemo-photodynamic therapy, which overcomes the multidrug
resistance of cancer cells and the low efficiency of PDT due to
hypoxia in cancer cells.
To obtain luminescent MOFs using fluorescent salts, Singh
et al. synthesized five different fluorescent nanosized salts/
NMOFs by reacting 1,5-naphthalenedisulfonic acid (NDS) and
Cu(NO3)23H2O with a variety of N-heterocyclic ditopic pyridyl
based highly fluorescent sensitizers, i.e., 9,10-bis((E)-2-(pyridin-
4-yl)vinyl)anthracene (B4PVA), 9,10-bis((E)-2-(pyridin-3-yl)vinyl)
anthracene (B3PVA), and 3,30-(peroxybis(methylene))dipyridine
(3PBP) by a diffusion method.70 The resulting fluorescent
nanoparticles (FNP) – [NDS2B4PVA2+S] (FNP 1a), [NDS2
3PBP2+MeOHH2O] (FNP 1b), [CuNDSB4PVA] (FNP 1c), [Cu
NDSB3PVA] (FNP 1d), and [CuNDS3PBP] (FNP 1e) – were of
sizes below 100 nm, exhibited supramolecular architectures of
the salts/MOFs, and showed high fluorescence arising from
pyridylvinyl in the MOF scaffold. The synthesized particles
had low cytotoxicity and a clear strong fluorescence signal in
the green channel within HeLa and MCF-7 cell lines at the
concentration of 10 mg mL1 (Fig. 6).
Drugs. Doxorubicin (DOX) is an important chemotherapy
agent which inhibits DNA replication by intercalating into the
DNA double helix and inducing free radical generation.92,93
Fig. 5 (a) TEM image of AuNR@MOFs showing the core–shell structure. (b)
EDX elemental mapping of AuNR@MOFs. (c) Fluorescence images of a 4T1
tumour-bearing mouse at different time points after being injected with
AuNR@MOFs@CPT. (d) Ex vivo fluorescence images of major organs and
tumour at 24 h post-injection. (e) Time-dependent quantitative fluorescence
intensity detected in tumour tissues. (f) Quantitative fluorescence intensity of
major organs and tumour. (g) Concentration of gold in major organs and
tumour measured by ICP-AES at 24 h post-injection. Irradiation time-
dependent (h) in vivo thermal images and (i) temperature change curve of
mice after being injected with PBS (control) and AuNR@MOFs@CPT under
808 nm laser irradiation. Reproduced with permission.80 Copyright (2017)
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
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However, direct administration of the drug causes undesired
side effects by affecting both malignant and non-malignant
cells in the body. Therefore, the delivery of the drug has been
mostly studied with nanocarriers, and DOX was the first drug to
receive clinical approval as a nanoformulation, delivered by a
PEGylated liposome.94 In addition to the apoptotic effects, its
highly fluorescent nature makes the drug a popular agent to
allow nanocarriers to be used as imaging agents as well as
therapeutics.95,96 Due to the high drug loading capacity, DOX
has been widely studied with MOF structures for both therapy
and imaging of tumour tissues.13,34,66–68 For example, Li et al.
reported the application of DOX loaded UiO-68-type NMOFs
(isoreticular extensions of UiO-66 with terphenyl-based ligands)
with a tumour-targeting agent (folic acid, FA) as targeted
therapy and imaging system for hepatoma (HepG2) both
in vitro and in vivo.66 The NMOFs were prepared as shown in
Fig. 7, firstly by the synthesis of Mi-UiO-68 from the maleimide-
modified terphenyl ligand, H2L, and ZrCl4 in a DMF solution at
120 1C, followed by their DOX loading to produce DOX@
Mi-UiO-68, and finally their decoration with thiolated FA units
via a thiol–maleimide Michael-type addition. The obtained
DOX@UiO-68-FA exhibited higher antitumour efficacy compared
to free DOX and FA-undecorated DOX@Mi-UiO-68, which was
confirmed by cell imaging via DOX, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay, and
in vivo studies using a HepG2 subcutaneous xenograft murine
model (Fig. 7).
2.1.2. Lanthanide MOFs. Materials based on lanthanide
fluorescence have attracted great attention due to their sharp
and stable emission, large and effective Stokes shifts, long-lived
fluorescence lifetimes, and improved spectral and time-
resolved signal discrimination from background
autofluorescence.97 Most of the luminescent lanthanide cations
are notably resistant to photobleaching in a broad range of
environmental conditions compared to organic fluorophores,
which ensures their repeated usage over long periods of
time.98,99 In addition, the luminescence of lanthanide ions
can be dramatically enhanced using a photonic converter, such
as an organic chromophore, through the ‘‘antenna effect’’.100
The molecules acting as antennae must be closely located to
the lanthanide to enable sensitization. Lanthanide MOFs
(Ln-MOFs) such as Eu-MOFs, Tb-MOFs and Yb-MOFs are
therefore excellent luminescent particles, closely connecting
lanthanide metals to p-conjugated organic linkers, which act
as antennae, and typically exhibiting good photostability
and characteristic fluorescence emission.23,101,102 For example,
Abazari et al. have reported the synthesis of a luminescent
amine-functionalized Eu-MOF, Eu:TMU-62-NH2 (TMU stands
for Tarbiat Modares University) with 9-coordinate Eu(III) centres
Fig. 6 (a) Schematic illustration for the synthesis of five different
fluorescent nanosized salts/NMOFs. (b) Confocal laser scanning
microscopy images of HeLa cells treated with FNP 1a–1e with a concentration
of 10 mg mL1 for 1 h. Reproduced with permission.70 Copyright (2018)
American Chemical Society.
Fig. 7 Schematic of the synthesis and application of DOX loaded and FA
conjugated Mi-UiO-68 MOFs for targeted cell imaging and antitumour
therapy. Reproduced with permission.66 Copyright (2016) The Royal
Society of Chemistry.
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connected by BDC-NH2 into a MOF with formula [Eu2(BDC-
NH2)3(DMF)4]n, which was conjugated with folic acid (FA) for
targeted delivery of the anticancer drug 5-fluorouracil (5-FU)
to MCF-7 breast cancer cells with concomitant in vitro
fluorescence cell imaging.103 Microscopy images exhibited
higher cellular uptake of the folic acid conjugated structures
compared to the unconjugated ones confirming the targeting
effect of FA, and also red fluorescence emission arising from
Eu:TMU-62-NH2 which can be used for imaging. 5-FU-loaded
FA@Eu:TMU-62-NH2 showed excellent release of 5-FU in an acidic
environment, implying pH-controlled release characteristics of
this material, which is very suitable to target solid tumours. In
addition, the nanoparticles dramatically decreased the cell viability
of MCF-7 cells in a time- and dose-dependent manner, and
increased reactive oxygen species (ROS) generation and apoptosis
compared to free 5-FU.
On the other hand, many lanthanide cations emit in the NIR
window of the optical spectrum, which allows deeper tissue
imaging than visible light. This is due to the higher tissue
penetration of NIR light as a result of lower scattering and
absorbing effects of tissues at longer wavelengths, which also
provides lower background fluorescence, less signal loss, and
thus a higher signal to background ratio.23,104 For example,
Gallis et al. have reported the construction of a novel multi-
functional MOF materials platform based on rare-earth (Eu,
Nd, Yb, Y, and Tb) hexanuclear single metal clusters, as well as
tuned compositions of Nd/Yb (Nd0.67/Yb0.33 and Nd0.46/Yb0.54)
coordinated by 2,5-dioxybenzene-1,4-dicarboxylate (DOBDC) in
the UiO-66 topology with general formula [Ln6(OH)8(DOBDC)5-
(DOBDC-H2)(H2O)6]n.
73 The synthesized MOF materials
exhibited both porosity and tunable emission properties over
a wide range, from deep red into the second NIR window
(B614–1350 nm) as a function of the metal identity. In addition
to this, they met fundamental prerequisites for relevance to
biological applications by demonstrating minimal in vitro
cytotoxicity and maintaining crystallinity under relevant physio-
logical conditions such as water and phosphate-buffered saline
(PBS). The group used EuDOBDC nanoparticles as a proof-of-
concept system in this series for in vitro imaging of RAW
264.7 mouse macrophage and HeLa human cervical cancer cells.
Their results presented an efficient discrimination between
the Eu emission and cell autofluorescence and a long-term
conservation of the intrinsic emission in live cells, proving the
application of the materials as long-term imaging agents.
Similarly, Foucault-Collet et al. have designed NIR-emitting
MOFs using NIR-emitting Yb(III) lanthanide cations and
phenylenevinylene dicarboxylate (PVDC) as a sensitizer-ligand
for NIR imaging in living cells.23 The sensitizers embedded
in the nano-Yb-PVDC-3 MOF structure (Fig. 8a–c), formula
[Yb2(PVDC)3(DMF)4]n, served as antennae as a result of the
overlap between the excitation spectra of nano-Yb-PVDC-3
MOFs and the absorbance spectra of H2-PVDC, which ensures
the energy transfer from the excited sensitizer-ligands to the
Yb(III) cations. NIR images demonstrated highly efficient
discrimination between the nano-Yb-PVDC-3 MOFs and auto-
fluorescence of cells, with emission visible from both the PVDC
linker and the Yb(III) ion, providing efficient imaging despite
the relatively low quantum yield of the MOFs in water that
arises from the energy level of the –OH overtone vibration being
so close to that of Yb(III) (Fig. 8d and e).
The colloidal stability of MOF nanoparticles is a challenging
issue to overcome for their in vivo application. Park et al.
reported a very facile solution to prepare water-dispersible
luminescing MOFs using a simple hand-grinding technique.
Tb-MOFs, composed of Tb(III) ions and tripodal carboxylate
ligands such as triazine-1,3,5-tribenzoic acid, were stabilised
by facile mechanical grinding with a biocompatible and
biodegradable surfactant (Pluronic F127), a triblock copolymer
composed of two poly(ethylene glycol) blocks at both of the
termini of a poly(propylene oxide) block.30 The particles were
also employed as drug delivery agents by encapsulating the
anticancer drug DOX, and acted as a multifunctional biomaterial,
which demonstrated efficient cell imaging and cancer cell killing
by drug delivery. In another study, Wang et al. reported multi-
functional water-soluble NaLnF4@MOF-Ln (Ln = Y, Tm, Yb, and
Eu) nanocomposites with dual-mode luminescence by combining
the anti-Stokes luminescence of NaYF4:Tm(III)/Yb(III) nanocrystals
with the Stokes luminescence of mesoporous lanthanide MOFs
Fig. 8 (a) Crystal structure of Yb-PVDC-3. (b) Powder X-ray diffraction
(PXRD) patterns of simulated and bulk Yb-PVDC-3 as well as as-synthesised
and purified nano-Yb-PVDC-3. (c) SEM image of nano-Yb-PVDC-3. Visible
and NIR microscopy images of nanoYb-PVDC-3 in (d) HeLa cells and (e) NIH
3T3 cells: (i) Bright-field, (ii) H2-PVDC emission (lex = 377/50 nm, lem = 445/
50 nm), (iii) Yb(III) emission (lex = 377/50 nm, lem = long pass 770 nm)
images. Reproduced with permission.23 Copyright (2013) National Academy
of Sciences.
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(MOF-Y:Eu(III)), constructed from Ln(NO3)3 (Ln = 95% Y + 5% Eu)
and BTC.105 The resulting NaYF4:Tm(III)/Yb(III)@MOF-Y:Eu(III)
nanocomposites were coated by polyvinylpyrrolidone (PVP)
to promote their cellular uptake and loaded with DOX. The
NaLnF4@MOF-Ln nanocomposites exhibited a unique anti-
Stokes blue fluorescence and Stokes red fluorescence under laser
excitation at a specific wavelength and showed bright blue
emission in HeLa cells under a fluorescence microscope with a
980 nm source. DOX release studies revealed the pH-dependence
of the drug release from the nanocarriers showing higher release
rate in the simulated acidic cancer cell environment.
2.1.3. Combination with luminescent nanoparticles. In
addition to organic fluorophores and luminescent metal ions,
incorporation of luminescent nanoparticles to MOFs is another
common approach to obtain luminescent MOF structures.
Persistent luminescent nanoparticles (PLNPs),74,75 upconversion
nanoparticles (UCNPs)76–78 and quantum dots (QD)79 are the
most popular emitting nanoparticles combined with MOFs.
Persistent luminescent nanoparticles. Among these luminescing
structures, persistent luminescent nanoparticles (PLNPs) possess
a unique optical phenomenon wherein continuous emission
takes place for seconds or hours even after removal of the
excitation source.106 Based on these superiorities, Xie and
co-workers have recently reported combination of ZIF-8 nano-
particles (tetrahedral zinc(II) ions connected by 2-methy-
limidazolate (mIm) linkers, formula [Zn(mIm)2]n) with
chromium-doped zinc gallogermanate (ZGGO) near-infrared
PLNPs. This results in a core–shell multifunctional nanoplatform
emitting in the NIR spectral region of the optical spectrum,
for elimination of autofluorescence and obtaining deep tissue
penetration and low irradiation damage under in vivo
conditions.74 ZGGO@ZIF-8 particles were prepared by nucleation
crystallization of a ZIF-8 shell on the surface of ZGGO particles.
In the study, the PLNPs offered long-term NIR persistent
luminescent signals for autofluorescence-free bioimaging with
red-light-rechargeable properties while biocompatible ZIF-8 – a
well-known pH responsive MOF – provided a shell structure to
accommodate the fluorescent anticancer drug DOX (Fig. 9a). The
fabricated ZGGO@ZIF-8-DOX multifunctional nanoplatform
achieved dual imaging of 4T1 murine breast adenocarcinoma
cells by DOX fluorescence and NIR persistent luminescence, and
additionally acted as a pH-responsive drug delivery system. The
particles showed quite high DOX loading (93.2%) and a drug
release profile accelerated in acidic conditions, as well as effective
in vivo tumour imaging (Fig. 9b–f) and suppression. Around the
same time, Yang and co-workers prepared similar ZGGO@ZIF-8
materials, also by a surface adsorption induced self-assembly of
MOFs on the ZGGO PLNPs, and generated comparable results,
with enhanced luminescence in the acidic tumour microenviron-
ment, and achieved tumour specific in vitro and in vivo imaging.75
These closely related examples are typical of the incorporation of
multiple imaging/therapeutic factors into one MOF-based DDS.
Upconversion nanoparticles. Luminescent UCNPs possess an
advantageous optical characteristic in their conversion of long
wavelength excitation (usually NIR) to short visible wavelength
emission. This feature helps them provide deep light penetration
in biological tissues, minimized background auto-fluorescence,
narrow emission peaks, and high photostability.76,107 The combi-
nation of MOFs with UCNPs can not only enable luminescence
imaging but also prevent undesired tissue damage associated
with UV excitation. These superiorities have driven researchers
to construct upconversion NMOFs as optical imaging and
drug delivery agents integrating the distinct advantages of both
structures. For example, Chowdhuri et al. prepared upconversion
NMOFs constructed by the direct coating of folic acid (FA)-
encapsulated ZIF-8 on NaYF4:Yb(III)/Er(III) UCNPs, as depicted in
Fig. 10a.76 X-ray diffraction (XRD) studies confirmed the successful
combination of NaYF4:Yb(III)/Er(III) UCNPs with ZIF-8, showing
characteristic diffraction peaks of both nanoparticles (Fig. 10b),
with a very small decrease in the initial optical intensity of UCNPs
(Fig. 10c). The prepared UCNP@ZIF-8/FA nanocomposites were
subsequently loaded with the anticancer drug 5-FU by adsorption
Fig. 9 (a) Schematic representations of (i)–(iii) the synthesis of core–shell
ZGGO@ZIF-8 multifunctional nanoparticles and (iv) loading with anti-
cancer drug DOX. (b) In vivo persistent luminescence imaging of a mouse,
intravenously injected with ZGGO@ZIF-8 (0.2 mL, 1 mg mL1 in PBS) under
254 nm irradiation for 5 min, (c) after in situ 661 nm LED recharging for
2 min, and (d) after a further interval of 10 min. (e) Ex vivo persistent
luminescence imaging after 24 h administration, conducted after 661 nm
LED recharging for 2 min and (f) the corresponding total luminescence of
major organs in the mouse. Reproduced with permission.74 Copyright
(2018) American Chemical Society.
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into the MOF nanostructure, which resulted in a high drug loading
(685 mg g1). The upconversion NMOFs functioned efficiently as
imaging agents, producing strong fluorescence signals under
in vitro conditions with HeLa cells and the FA conjugated UCNP@
ZIF-8 showed higher cellular penetration compared to the particles
without FA (Fig. 10d). In addition, the as-prepared 5-FU loaded
UCNP@ZIF-8/FA nanocomposites showed higher drug release in
acidic conditions, suggesting a pH-responsive drug release from
the structures, and also induced greater cytotoxicity towards HeLa
cells than L929 mouse fibroblast cells due to the higher cellular
internalization in HeLa cells though folate receptor (FR)-mediated
endocytosis.
The group also reported the fabrication of NaYF4:Yb(III)/
Er(III) UCNPs combined with FA encapsulated UiO-66-NH2
NMOFs (a structural analogue of UiO-66, where the linker is
BDC-NH2) using a similar synthetic approach and employed
them as targeted drug delivery agents loading with DOX anti-
cancer drug.77 The obtained DOX loaded UCNP@UiO-66-NH2/
FA nanoparticles improved the therapeutic efficacy of DOX
compared to UCNP@UiO-66-NH2 by higher cellular uptake
through FR-mediated endocytosis, and also enhanced the
fluorescence imaging efficiency in vitro.
In another study, an in situ self-assembly strategy was
reported by Yuan et al. to prepare upconversion NMOFs.78
The strategy allowed the coating of positively charged UCNPs with
different, negatively charged Zr-MOFs, including UiO-66, UiO-66-
NH2, MOF-801, and PCN-223, a 12-connected Zr-porphyrin MOF
with formula [Zr6O4(OH)4(TCPP)3]n, through electrostatic inter-
actions. The homogeneous distribution of NaYF4:Yb/Er UCNPs,
composed of hexagonal NaYF4 UCNPs, doped with Yb/Er
(18/2 mol%), on the MOF surface enabled uniform upconversion
luminescence (UCL) on the microscale or single-particle scale. This
is promising in a wide range of applications including
luminescence-monitored drug delivery, which was shown by
DOX release from the nanocomposites, as well as photodynamic
therapy, due to the high singlet oxygen generation efficiency of
PCN-223@NaYF4:Yb/Er nanocomposites under the excitation of
980 nm light, by the energy transfer from UCNPs to the TCPP
linkers of PCN-223.
Quantum dots. Quantum dots (QDs) are semiconductor
nanocrystals usually in the size range of 2–10 nm (10–50 atoms),
with a structure between bulk and molecular forms, which
enables size dependent fluorescence. Narrow photolumines-
cence bands, broad absorption windows, large molar extinction
coefficients, low photobleaching, high quantum yield, and high
chemical stability are the major advantages over conventional
chromophores.108,109 These remarkable features make them
promising optical imaging agents in various application areas,
and their combination with MOFs has therefore attracted great
attention in recent years.47,79,110,111 In particular, fluorescent
carbon nanodots (C-dots) are a novel class of QDs and nano-
carbons, displaying strong fluorescence intensity with high
physicochemical stability and low toxicity compared with toxic
metal-based QDs, which is highly relevant for biomedical use.112
As an example, He et al. integrated these with MOF nanoparticles
to obtain C-dot-encapsulated MOF nanocomposites for fluorescence
imaging of cancer cells and simultaneous pH-responsive drug
delivery.79 The particles were prepared by directly mixing
synthesized green fluorescent C-dots with Zn(NO3)26H2O and
2-methylimidazole, the precursors to ZIF-8, at room temperature
in methanol without stirring for 24 h. The fluorescence intensity
and size of the resulting C-dots@ZIF-8 nanoparticles (NPs) were
tuned by varying the amount of C-dots and the concentration of
the precursors. The NPs were further loaded with 5-FU and
employed as pH-responsive anticancer drug delivery vehicles
with simultaneous fluorescence imaging of cancer cells (Fig. 11).
2.1.4. Two-photon responsive MOFs. Two-photon (TP)
fluorescence imaging is a powerful imaging technique, in
which fluorophores are excited by simultaneous absorption of
two photons in the NIR region that results in emission of a
single photon of higher energy in the visible spectrum, thereby
Fig. 10 (a) Schematic illustration of the synthetic route to FA encapsulated
and 5-FU loaded upconversion MOF composites, 5-FU loaded UCNP@
ZIF-8/FA, as a targeted and pH responsive anticancer drug delivery agent.
(b) PXRD patterns of the fabricated UCNPs, ZIF-8, and UCNP@ZIF-8/FA.
(c) Emission spectra of UCNP and UCNP@ZIF-8/FA (lex = 980 nm).
(d) Fluorescence microscopy images of HeLa cells incubated with
5 mg mL1 of UCNP@ZIF-8/FA (upper) and UCNP@ZIF-8 (lower) for 6 h at
37 1C, with the corresponding bright field and overlay images. Reproduced
with permission.76 Copyright (2016) The Royal Society of Chemistry.
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allowing deeper tissue penetration and minimized tissue auto-
fluorescence and photo-induced damage compared to conven-
tional one-photon imaging techniques.113–116 NMOFs with high
porosity and periodic structures not only enable efficient loading of
drugs but can also accommodate two-photon responsive chromo-
phores. In addition, the photophysical properties of the imaging
agents can be modified by the confinement effect in nanoscale
pores, as reported by Maza et al. using UiO-67 doped with a
photoactive metal polypyridyl complex of ruthenium(II) bis(2,20-
bipyridine)(2,20-bipyridyl-4,40-dicarboxylic acid) dichloride,117 or
ruthenium(II) bis(2,20-bipyridine)(2,20-bipyridyl-5,50-dicarboxylic
acid) dichloride,118 which resulted in dramatic increase in
luminescence lifetime of the Ru complexes.
Similarly, Chen et al. have incorporated the cationic
ruthenium(II) tris(bipyridyl) complex, [Ru(bpy)3]
2+, into UiO-67
MOFs for in vitro two-photon fluorescence (TPF) imaging and
PDT.119 The theranostic nanoparticles were prepared by soaking
the UiO-67 nanoparticles in a DMF solution of [Ru(bpy)3](PF6)2 at
90 1C. Trapping of the [Ru(bpy)3]
2+ guest molecules in the MOF
structures dramatically improved their quantum yield (Fig. 12a),
luminescence lifetime (Fig. 12b), and TPF intensity (Fig. 12c) as a
result of the steric confinement effect of MOF pores. The
obtained nanoparticles, with an average diameter of B92 nm,
showed improved stability upon light exposure, which resulted
in a strong in vitro cell-killing effect and effective photodynamic
therapy towards A549 human lung cancer cells by generating
singlet oxygen upon non-invasive light irradiation, while
exhibiting good biocompatibility without irradiation (Fig. 12d).
Confocal laser scanning microscopy (CLSM) images confirmed
that UiO-67-[Ru(bpy)3]
2+ NPs were successfully internalized into
A549 cells and demonstrated efficient in vitro TPF imaging
capability with red fluorescence in the cytoplasm under
880 nm light irradiation (Fig. 12e and f).
In order to obtain more effective intracellular sensing and a
deep tissue imaging agent, Yang et al. also integrated the
advantages of two photon excitation with MOFs, obtaining a
Fig. 11 (a) HRTEM image of C-dots (inset shows an HRTEM image of a
single C-dot). SEM images of (b) C-dots@ZIF-8 and (c) ZIF-8 (insets
represent the corresponding TEM images). Photoluminescence (PL) spectra
of (d) bare C-dots, (e) C-dots@ZIF-8, and (f) pure ZIF-8 (lex = 420 nm).
Insets are the photographs of the corresponding samples suspended in
methanol solution under ambient light (left) and under 365 nm UV light
(right). (g) In vitro cytotoxicity of HeLa cells incubated with C-dots@ZIF-8,
free 5-FU and 5-FU loaded C-dots@ZIF-8. (h) The differential interference
contrast (DIC), and (i) confocal laser scanning microscopy (CLSM) images of
HeLa cells incubated with 5-FU loaded C-dots@ZIF-8 for 24 h. Reproduced
with permission.79 Copyright (2014) The Royal Society of Chemistry.
Fig. 12 (a) One-photon photoluminescence spectra, (b) time-resolved
luminescence decay curves, and (c) two-photon fluorescence (TPF)
spectra of Ru(bpy)3
2+ and the (nUiO-67)-Ru(bpy)3
2+ NPs. (d) Cell viability
of A549 cells with/without light irradiation after being treated with
(nUiO-67)-Ru(bpy)3
2+ NPs at different concentrations (l 4 400 nm,
200 mW cm2, 10 min). CLSM images of A549 cells (e) treated with
(nUiO-67)-Ru(bpy)3
2+ NPs (upper) and (f) untreated (lower) for 12 h. Blue
fluorescence indicates Hoechst 33342 nuclei staining. Red shows nano-
particles (lex = 880 nm, lem = 580–660 nm). The scale bar is 50 mm.
Reproduced with permission.119 Copyright (2017) American Chemical Society.
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TP-MOF composite to detect H2S or Zn(II) as model analytes in
living tissues, and also to visualize tissues.120 PCN-58, a bis-
azidomethyl functionalised analogue of the large-pore Zr MOF
UiO-68 comprised of 20,50-bis(azidomethyl)-[1,10:40,100-terphenyl]-4,
400-dicarboxylate, (TPDC-2CH2N3) coordinated with Zr6 clusters,
can be conjugated with target-responsive two-photon organic
moieties by Cu(I)-catalysed azide–alkyne cycloaddition (CuAAC)
without any cross reactivity towards the MOF structure itself.
PCN-58 was reacted with 6-amino-2-(prop-2-yn-1-yl)-1H-benzo[de]
isoquinoline-1,3(2H)-dione (alkynyl-BR-NH2) and then the
amino group of the structure turned into an azide group by
the use of tert-butyl nitrite and trimethylsilyl azide to obtain
probe 1 for H2S detection. To achieve probe 2 for Zn(II) detection,
PCN-58 was reacted with 2-(bis(pyridin-2-ylmethyl)amino)-N-(1,3-
dioxo-2-(prop-2-yn-1-yl)-2,3-dihydro-1H-benzo[de]bisoquinolin-6-yl)
acetamide (alkynyl-DL). The constructed TP-MOF probes
containing the different two-photon fluorophores were
successfully employed in live cells and tissue slices (rat liver
and lung tissue), using two-photon microscopy (excited at l B
820 nm) with a tissue penetration depth of 130 mm to detect
H2S and Zn(II), as well as visualize tissues.
Cumulatively, these examples of emissive MOFs and composites
highlight the wide range of strategies available to prepare materials
for biological imaging. The use of intrinsically luminescent linkers,
such as porphyrins, is highly attractive for its simplicity, but many
organic fluorophores do not possess highly symmetric structures,
which is often a requirement for synthesis of ordered, porous
MOFs. Likewise, the coordination chemistry of the lanthanides,
which is dominated by steric factors, often results in denser
structures with limited porosity. Hence, for combined imaging
and drug delivery, postsynthetic incorporation or hybridisation
with fluorophores is often the more advantageous approach.
2.2. Magnetic resonance imaging
Magnetic resonance imaging (MRI), founded on the principles
of nuclear magnetic resonance (NMR), has become an essential
tool for clinical diagnosis over the past few decades. MRI is a
non-invasive imaging modality that uses non-ionizing radiation
in the radio frequency range and does not employ any radio-
isotopes, unlike computed tomography and traditional X-rays.
It offers harmless tissue imaging with high spatial resolution
and tissue contrast, and superb depth of penetration. MRI
detects spin reorientation in a magnetic field, and hence
provides detailed anatomic images of soft tissues with 3D
imaging capability, such as imaging of the brain, heart, and
cartilage, as well as detection of tumours and the assessment of
therapeutic responses.121,122 MRI signals are produced by the
NMR signals of the water protons (1H nuclei) in a specimen.38
However, the intrinsic low signal difference between diseased
and normal tissues can be insufficient to detect lesions.
To enhance the signal differences between the tissues, MRI
contrast agents have been developed to improve the contrast at
the region of interest by altering the magnetic fields and
accelerating relaxation processes. In the absence of an external
magnetic field, the magnetic moments of 1H nuclei are
randomly oriented. However, in the external magnetic field of
an MRI scanner, the magnetic moments of 1H nuclei are
aligned through an applied radio frequency pulse. Upon the
removal of radio frequency perturbation, the 1H nuclei undergo
a recovery process which usually occurs by two different types of
relaxation time: longitudinal relaxation, characterized by the
parameter T1 (spin–lattice relaxation time), and transverse
relaxation, characterized by the parameter T2 (spin–spin
relaxation time).123,124 Depending on the type of the relaxation
time, the contrast agents are sorted into two main categories: T1
agents shorten the longitudinal (spin–lattice) relaxation time of
the surrounding water protons, and provide a positive contrast
and brighter MRI images, whereas T2 agents shorten the
transverse (spin–spin) relaxation time of the water protons
and create a negative, dark contrast effect.121,123 The efficiency
of a contrast agent is determined by the ratio between transverse
(r2) and longitudinal (r1) relaxivity values, which are defined as
the slope of a plot of 1/T2, and the slope of a plot of 1/T1 vs. the
concentration, respectively.125 A lower value of r2/r1 (between
1 and 3) indicates T1 type, while higher values (410) indicate T2
type. Between these values, the materials can show dual contrast
characteristics.126
MRI is a powerful imaging modality, however it requires the
administration of contrast agents in large doses to enable
adequate MRI contrast in target tissues.38 For clinical applications,
the most widely used MRI contrast agents are paramagnetic
gadolinium (Gd) chelates, which act as T1 contrast agents
producing signal enhancement in T1-weighted images.
127–129 Small
molecule Gd chelates show modest r1 values (B4–5 mM
1 s1), so
require high doses for an effective contrast. Moreover, the
release of free Gd ions from unstable Gd complexes has been
associated with nephrogenic systemic fibrosis in renal failure
patients and the use of some of the gadolinium based contrast
agents was banned in Europe in spring 2007.127,128,130–133
However, the use of the most stable gadolinium-based contrast
agents at the lowest possible dose has been mostly commonly
accepted as the optimal protocol.131,134
Recently, NMOFs have become a promising alternative to Gd
complexes as potential MRI agents, due to their large metal
payload, low toxicity, superior stability, and higher relaxivity
values, which provide stronger contrast enhancement with
lower doses and hence improve diagnostic sensitivity.53 MOF
contrast agents can be designed either as T1, T2 or combined T1
and T2 contrast agents by building the structure with MRI active
paramagnetic metals as intrinsic components, or combining
synthesized MOFs with various MRI contrast agents. Furthermore,
they can be simultaneously utilized as drug delivery agents, and
directed to a specific area interested in the body by conjugation of
various cell targeting ligands.135 Gd-Based MOFs, Mn-based MOFs
and Fe-based MOFs have been developed as promising candidates
as MRI contrast agents in the literature.28,136–138
2.2.1. Gd-Based MOFs. Gadolinium metal organic frame-
works (Gd-MOFs) have emerged as an alternative to Gd chelates
to enhance the per-metal-based relaxivity values of Gd
complexes and decrease the concentrations used in imaging
applications.22,28,40 Gd-MOF nanoparticles were used as MRI
contrast agents for the first time by Lin and co-workers in
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2006.28 The two MOFs used in the study were synthesized by a
reverse microemulsion technique. [Gd(BDC)1.5(H2O)2]n nano-
rods of different sizes resulted from the combination of GdCl3
and bis(methylammonium) benzene-1,4-dicarboxylate in the
cationic cetyltrimethylammonium bromide (CTAB)/isooctane/
1-hexanol/water system, while mixing GdCl3 and tri-(methylam-
monium) benzene-1,2,4-tricarboxylate (1,2,4-BTC) in the CTAB/
isooctane/1-hexanol/water microemulsion system resulted in
crystalline nanoplates of [Gd(1,2,4-BTC)(H2O)3]n, with a diameter
of B100 nm and an average thickness of 35 nm. Both NMOFs
showed very high r1 and r2 relaxivities on a per mM of Gd(III)
basis and extraordinarily high r1 and r2 relaxivities on a per mM
of nanoparticle basis. In 2008, the group showed surfactant-
assisted synthesis of two novel nanoscale Gd-MOFs, block-like
particles of [Gd2(BHC)(H2O)6]n with a fluorite topology and
[Gd2(BHC)(H2O)8]n with an inverse rutile topology (BHC stands
for benzene-1,2,3,4,5,6-hexacarboxylate) at elevated temperatures
by controlling the pH values of the reaction medium.40 Particles
of [Gd2(BHC)(H2O)6]n showed a modest longitudinal relaxivity
(r1) of 1.5 mM
1 s1, but significantly high transverse relaxivity
(r2) value of 122.6 mM
1 s1 on a per-Gd basis, providing a
strong contrast in magnetic resonance.
Hatakeyama et al. reported the control of size and shape by
incorporation of hydrotropes into the reverse microemulsion
synthesis of Gd-MOF nanoparticles with a general composition
of [Gd(1,4-BDC)1.5(H2O)2]n and [Gd(1,2,4-BTC)(H2O)3]n.
22
Hydrotropes are defined as compounds that offer both hydro-
phobic and hydrophilic features. Specifically, sodium salicylate,
used amongst various hydrotropes in the study, exhibited the
best size reduction, producing Gd-MOF nanoparticles of an
average size of 82 nm with the highest total surface area.
The increase in the outer surface areas of the nanoparticles
provided enhanced longitudinal relaxivity values (r1) up to
83.9 mM1 s1, which is nearly 20 times higher than that of
Magnevist (gadopentetate dimeglumine), a clinical positive
contrast agent used for comparison in the study. Wang et al.
reported the preparation of NMOF-based T1–T2 dual-modal
contrast agents for MRI by using a mixture of Eu(III) and
Gd(III) as metallic nodes, isophthalic acid (H2IPA) as building
blocks, and PVP as a surfactant. The produced spherical
Eu,Gd-NMOFs were also coated by a silica layer to improve
the particle stability and functionalized with c(RGDyK), a
tumour-targeting peptide sequence, which targets integrin
avb3.
19 The Eu,Gd-NMOF@SiO2 nanoparticles showed high
longitudinal (38 mM1 s1) and transversal (222 mM1 s1)
relaxivities by inducing signal enhancement on T1- and signal
attenuation on T2-weighted images when injected in vivo.
2.2.2. Mn-Based MOFs. Paramagnetic Mn(II) ions are
known as potent T1 MRI contrast agents, functioning similarly
to gadolinium but showing less toxicity.139,140 Mn also possesses
a minor T2 effect by causing darkening in MR images. Mn(II) ions
are natural cellular constituents involved in mitochondrial
processes, which makes their uptake highly dependent on
mitochondrial metabolism and mitochondrial density in the
cells, and they can be an effective contrast agent for the liver
and other mitochondria-rich organs like the pancreas and the
kidneys.121,139 These characteristics have directed researchers
to develop Mn-based MOFs.21,141,142 Lin’s group reported the
synthesis of [Mn3(BTC)2(H2O)6]n with controllable morphology
using reverse-phase microemulsion procedures, subsequently
coating the Mn MOFs with a silica layer and functionalizing
with a cyclic arginine–glycine–aspartate (RGD) peptide for cancer
targeting. The yielded nanostructures demonstrated target-
specific MRI providing high contrast enhancement.21 In another
study, Yang et al. showed the construction of a new type of
nanoscale metal–organic particles (NMOPs) via self-assembly of
Mn(II) ions and a NIR dye, IR825, as bridging ligand, which
were further encapsulated within a polydopamine (PDA) shell
and functionalized with PEG, for imaging-guided photothermal
cancer treatment.141 The produced multifunctional particles
offered strong contrast in T1-weighted MRI owing to Mn(II) in
the structure of Mn-IR825@PDA-PEG NMOPs, while IR825
with strong NIR absorbance enabled efficient photothermal
conversion ability and high efficacy of photothermal therapy
(PTT) upon 808 nm laser irradiation, as well as a great photo-
stability under both in vitro and in vivo conditions.
Qin et al. reported the synthesis and comparison of two
water-stable Mn- and Gd-based MOFs of N-(4-carboxybenzyl)-
(3,5-dicarboxyl)pyridinium bromide (H3CmdcpBr), ([Mn2(Cmdcp)2
(H2O)2]H2O)n (1) and ([Gd(Cmdcp)(H2O)3](NO3)3H2O)n (2), and
showed their applications as strong MRI contrast agents under
in vivo conditions.142 The in vitro characterization demonstrated
that the Mn-based MOF possessed a slightly higher relaxivity r1
value (17.50 mM1 s1) compared with the Gd-based analogue
(13.46 mM1 s1), and both of them are superior to that of the
clinical positive contrast agent, Gd–DTPA (DTPA = diethylene
triamine pentaacetate, r1 = 4.87 mM
1 s1) used as a control in
the study (Fig. 13a and b). In vivo MR images of the Mn-based MOF
indicated that the nanoparticles have high contrast efficacy over a
prolonged timeframe enabling remarkable positive signal enhance-
ment in kidneys (Fig. 13c).
2.2.3. Fe-Based MOFs. Iron is one of the essential elements
in living organisms that is presented in abundance and has
fundamental and important roles in many different biological
processes, unlike gadolinium.143 Due to the high concentration
of iron in the body, the potential leakage of the element from
the MOF structures is not expected to cause any significant
damage and any free Fe to be metabolically eliminated.122
As opposed to Gd and Mn, iron-based MRI contrast agents
increase the rate of T2 relaxation and exhibit a negative image
enhancement, leading to dark contrast effects in MR images.
The MIL family of MOFs constructed from iron(III) and carboxylate
linkers have been shown to act as strong T2-weighted MRI
contrast agents in several studies.31,32 The pioneering work on
the development of iron-based MOFs as MRI contrast agents was
reported by Horcajada et al. in 2010.31 Non-toxic MIL-88A(Fe),
where iron(III) trimers, are connected by fumarate linkers into a
flexible hexagonal structure with composition [Fe3O(fum)3
(H2O)2X]n (X is a monocounterion typically OH
 or Cl), and
MIL-100(Fe) were synthesized in biologically and environmentally
favourable aqueous or ethanolic media, exhibit high transversal
(r2) relaxivities. Further functionalization of the particles by a
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H3C–PEG–NH2 coating increased the r2 values from 56 to
95 s1 mM1 for MIL-88A(Fe), and from 73 to 92 s1 mM1 for
MIL-100(Fe), by decreasing the aggregation of the MOFs in water.
Zhang et al. demonstrated an alternative application with
MIL-101(Fe) nanoparticles, in which the MOFs were utilized for
delivery of unmethylated cytosine–phosphate–guanine oligonu-
cleotides (CpG ODNs) to induce immune response in combination
with MRI.32 MIL-101(Fe) nanoparticles were post-synthetically
modified with CpG ODNs by p–p interactions. The nanoconjugates
showed stronger immune response than free CpG ODNs, and
high T2-MRI capacity both in vitro and in vivo, providing
promising proof-of-concept as immunostimulatory and imaging.
In another study, Fe-based MOF contrast agents were
constructed by chelating Fe(III) ions with a polydopamine coating
on the DOX loaded Zn-MOF, ZIF-8, synthesized via a one-pot
synthesis process.144 The ZIF-8 nanoparticles were further
conjugated by hyaluronic acid (HA), through iron-mediated
coordination, for targeted drug delivery and MRI in CD44 (a cell
surface HA-binding glycoprotein) overexpressed prostate cancer
cell line (PC-3). The multifunctional ZIF-8 nanoparticles showed
efficient intracellular uptake, and in vitro chemotherapeutic
efficacy compared to free DOX as well as favourable contrast
ability for MRI from the conjugated Fe(III) ions.
An alternative and effective strategy to design Fe-based
MOFs for MRI is to encapsulate superparamagnetic iron oxide
nanoparticles (SPIONs) into MOFs. SPIONs are clinically used
MRI contrast agents with an extraordinary ability to shorten T2
relaxation times due to their unique magnetic
properties.121,136,145 Zhao et al. reported novel theranostic
Fe3O4@UiO-66 core–shell composites, fabricated by in situ
growth of a UiO-66 MOF shell on a Fe3O4 core, for drug delivery
via UiO-66 and simultaneous MRI by the Fe3O4 nanoparticles
(Fig. 14a).136 The decrease in BET surface area (SBET) of UiO-66
MOFs confirmed the interior Fe3O4 core within UiO-66
(Fig. 14b) while the high saturation magnetization (Ms) value
showed their superparamagnetic characteristics (Fig. 14c).
The core–shell nanoparticles served as excellent T2 contrast
agents with a high transverse relaxivity (255.87 mM1 s1)
and significant darkening effect in HeLa cells at increased
concentrations (Fig. 14d), as well as in vivo MRI capability in
Kunming mouse and HeLa-tumour bearing mice at increased
incubation times (Fig. 14e and f). Furthermore, the particles
could be loaded with DOX for simultaneous cancer therapy,
and the obtained Fe3O4@UiO-66-DOX particles exhibited high
cell mortality and remarkable tumour size inhibition compared
with Fe3O4@UiO-66, both in vitro and in vivo.
In another study, Chowdhuri et al. showed the development
of a new magnetic porous system constructed by coating of
superparamagnetic Fe3O4 nanoparticle cores by a shell of
IRMOF-3, which is constructed from octahedral Zn clusters
and BDC-NH2 with formula [Zn4O(BDC-NH2)3]n, for MRI.
145
The nanoparticles were further functionalized by conjugation
of a cancer targeting ligand, folic acid, and a fluorescent
molecule, rhodamine B isothiocyanate, for simultaneous
fluorescence imaging. After loading with the anticancer chemo-
therapy drug paclitaxel, through hydrophobic interactions, the
NMOFs showed good therapeutic efficacy in HeLa cells, by high
internalization via receptor-mediated endocytosis, and strong
T2-weighted MRI contrast due to the high loading amount of
MR-active Fe3O4 nanoparticles. These latter examples show that
the MOF/nanoparticle hybrid route is an attractive alternative
to preparing MOFs with intrinsically magnetically active
metals, but the protocol does require additional synthetic steps
and additional components, which may complicate large scale
manufacture of any clinical MOF-based MRI contrast agents.
2.3. Computed tomography
Computed tomography (CT) is a non-invasive medical imaging
technique for 3D visualization of internal structures with high
spatial and temporal resolution. CT is based on the attenuation
of X-rays, which mainly uses contrast agents with high atomic
numbers (high-Z elements) showing high X-ray attenuation
ability, such as iodine, gold, barium, bismuth and gadolinium.
The attenuation values of most tissues are similar, which
makes the differentiation of diseased from normal tissue
difficult. However, by using contrast agents containing heavy
elements, the desired contrast enhancement can be
achieved.33,146,147 Currently available contrast agents in clinical
practice are mostly iodine derivatives that may cause severe
side effects, like thyroid dysfunction or renal toxicity, due to
small amounts of free iodine in the formulation.148,149 In
addition, these materials show non-specific distribution and
rapid pharmacokinetics, and therefore require administration
in high concentrations for enhanced CT imaging resolution.
To overcome these limitations, a number of MOF nanoparticles
containing high-Z elements have been recently developed and
employed as potential CT contrast agents. For example, Lin’s
Fig. 13 (a) T1-Weighted MR images of ([Mn2(Cmdcp)2(H2O)2]H2O)n (1)
and ([Gd(Cmdcp)(H2O)3](NO3)3H2O)n (2), as well as the commercial
contrast agent Gd–DTPA, at different concentrations in water. (b) The
plot of 1/T1 vs. the concentrations for each. (c) MR images of a female nude
mouse displaying the MR signal intensity in both kidneys at different time
points of intravenous post-injection with ([Mn2(Cmdcp)2(H2O)2]H2O)n.
Reproduced with permission.142 Copyright (2017) American Chemical
Society.
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group reported the construction of UiO-66 type NMOFs containing
high-Z elements (zirconium and hafnium) and showed their
applications as CT contrast agents.42,150 Zr and Hf have high
atomic numbers of 40 and 72, respectively, making them potential
CT contrast agents. In the study, as-synthesized UiO-66(Hf) nano-
particles were further coated with silica and PEG in order to
improve biocompatibility, and were employed for in vivo CT
imaging of mice, which resulted in higher attenuation in the liver
and spleen.42 Zhang et al. developed the concept by the synthesis
of an iodine-boron-dipyrromethene (BODIPY)-containing MOF,
named UiO-PDT, as a CT imaging agent.33 The nanocrystals
were functionalised by exchanging the diiodo-substituted
monocarboxyl-functionalized BODIPY (I2-BDP) with BDC linkers
at the surfaces of pre-synthesised UiO-66. The obtained UiO-PDT
nanocrystals exhibited no obvious severe acute or sub-acute
toxicity, even at high injection dosages, and provided good X-ray
attenuation – particularly for about 24 h after intravenous
administration – as well as high accumulation in the tumour
region of Sprague-Dawley rats bearing hepatomas (Fig. 15).
In principle, any MOF nanoparticle containing high-Z elements
in the linker, metal clusters, or surface functionality could be
applied to CT imaging.
2.4. Positron emission tomography
Positron emission tomography (PET) is a commonly used non-
invasive imaging modality that diagnoses abnormalities at the
cellular/molecular level and provides 3D images with high
sensitivity, specificity and limitless depth of penetration.151
PET requires internal administration of a molecule labelled
with a positron-emitting radionuclide known as radiotracer
(usually at nanomolar concentrations) into the bloodstream
of the patient. Various positron-emitting radionuclides, including
18F (t1/2 = 109.8 min),
11C (t1/2 = 20.39 min),
13N (t1/2 = 9.965 min),
15O (t1/2 = 2.037 min),
68Ga (t1/2 = 68 min),
64Cu (t1/2 = 12.7 hours),
89Zr (3.27 days) and 124I (t1/2 = 4.176 days), are used for PET
imaging in clinical applications.152,153 The natural decay of the
radionuclide comprises emission of a positron from the structure
and interaction of this emitted positron with a free or loosely
bound electron after it travels only a short distance through the
tissue. Ultimately, one positive electron is annihilated with one
negative electron, producing two photons which are given off in
opposite directions with a 511 keV energy.153 These high-energy
gamma-rays are detected with a PET scanner, and the distribution
of the radiotracer throughout the patient’s body is constructed as
a series of 3D images.
Based on these advantages, Hong and co-workers reported
the application of NMOFs as a radiotracer by developing an
intrinsically radioactive UiO-66 NMOF (89Zr–UiO-66) through
incorporation of a positron-emitting isotope of zirconium,
zirconium-89, during the synthesis.34 The particles were loaded
with DOX, and then further surface engineered with pyrene-
derived polyethylene glycol (Py–PGA–PEG) and an F3 peptide
ligand, to target nucleolin on tumour cells and enhance the
cellular uptake and drug delivery of the NMOFs in tumour
region (Fig. 16a). The particles showed strong radiochemical
and material stability in different biological media, as well as
relatively high drug loading capacity (1 mg DOX per mg
UiO-66), allowing them to be used as both a therapeutic agent
Fig. 14 (a) Schematic illustration for the preparation of theranostic Fe3O4@UiO-66 core–shell composites. (b) N2 adsorption–desorption isotherms and
(c) magnetization hysteresis curves of UiO-66 and Fe3O4@UiO-66 nanoparticles, confirming effective hybridisation. (d) In vitro T2-weighted MR images
of HeLa cells incubated with different concentrations of Fe3O4@UiO-66 composites (0, 25, 50, 100, 150 and 200 mg L
1) for 24 h and enhanced
darkening effect by concentration increase. (e) In vivo T2-weighted MR images of a Kunming mouse injected with the composites and the images at
different time points (red cycles show the liver region). (f) T2-Weighted MR images of HeLa tumour-bearing mice before and at 1 h and 9 h post-
intravenous injection with Fe3O4@UiO-66 (red cycles show the tumour region). Reproduced with permission.
136 Copyright (2016) The Royal Society of
Chemistry.
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and a fluorescence visualizer. By conjugation of F3 targeting
peptides, selective and enhanced uptake of 89Zr–UiO-66 con-
jugates towards MDA-MB-231 human breast tumour cells was
reported via PET images taken at different time points
after injection of MDA-MB-231 tumour bearing mice with the
nanoparticles (Fig. 16b). The results were further confirmed
by ex vivo organ distribution studies obtained by tissue gamma-
counting (Fig. 16c) and by ex vivo fluorescence imaging of DOX
in tumour-bearing mice.
In another example, Liu’s group reported the synthesis and
use of 64Cu radiolabelled and DOX loaded amorphous zeolitic
imidazolate framework-8 (AZIF-8) to investigate how particle size
affects the in vivo distribution of particles and their tumour
targeting ability, using an in vivo quantitative tracing strategy
based on PET imaging.154 The nanoparticles were synthesized in
different sizes by a rapid one-pot aqueous approach. To label the
particles with 64Cu, a chelator-free radiolabelling method, which
relies on doping of the structure by 64Cu(II) ions in the synthesis,
was conducted. The results showed that the intracellular drug
release rate increases as the size decreases, but CT imaging
shows smaller MOF nanoparticles (60 nm) circulate in the blood
longer and achieve over 50% higher tumour accumulation than
larger MOFs (130 nm), providing higher antitumour efficacy.
2.5. Photoacoustic imaging
Photoacoustic imaging (PAI), also known as optoacoustic imaging,
is a robust, non-invasive and non-ionizing biomedical imaging
technique that uses both optical and ultrasonic imaging to
visualize anatomical structures and physiological changes in
biological tissues. This hybrid imaging modality has received great
attention by effectively combining the high optical contrast of
optical imaging with the high penetration depth and ultrasonic
spatial resolution of ultrasound imaging.155,156 In PAI, tissue is
illuminated by short laser pulses, which cause a fast local
temperature increase as a result of the absorption of the incident
energy and, consequently, formation of a small and localized
thermal perturbation. This leads to generation of photoacoustic
(PA) pressure waves, which propagate inside the tissue owing to
thermal expansion, and these photoacoustic signals can be
detected with wideband ultrasound transducers. By measuring
the duration and arrival time of the pressure pulses to the
transducer, the location and size of the target tissue can be
Fig. 15 (a) Schematic representation of the construction of UiO-PDT
nanostructures as X-ray CT imaging agents. In vivo CT images of a
Sprague-Dawley rat at different time points after being injected with
UiO-PDT showing the (b) ventral, and (c) the lateral sides of the rat. (d)
3D images revealing the ventral sides of hepatic tumours, highlighted
with red circles. (e) The corresponding Hounsfield unit values indicating
the quantity of the attenuated signal. Reproduced with permission.33
Copyright (2017) The Royal Society of Chemistry.
Fig. 16 (a) Scheme for the synthesis for 89Zr-UiO-66/Py–PGA–PEG-F3 conjugates. (b) Coronal PET images of MDA-MB-231 tumour bearing mice at
different time points after being injected with 89Zr-UiO-66/Py–PGA–PEG-F3, 89Zr-UiO-66/Py–PGA–PEG, and 89Zr–UiO-66/Py–PGA–PEG-F3 with
excess F3 peptide for blocking. (c) The corresponding organ distribution at 120 h post-injection obtained by tissue gamma-counting. **P o 0.01.
Reproduced with permission.34 Copyright (2017) American Chemical Society.
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determined.157 In PA imaging, the sensitivity and specificity of the
image usually depends on the endogenous contrast. However, the
low intensity of internal PA signals in some tissues limits
the possibility of obtaining high contrast PA images. Exogenous
contrast agents have therefore been used to improve the image
quality by PA signal and imaging contrast enhancement.
Specifically, carbon nanotubes and noble metal nanoparticles –
in particular gold nanoparticles (AuNPs) and gold nanorods
(AuNRs) – have been popular in PAI, since they possess strong
light absorption ability due to their enhanced surface plasmon
resonance.158,159
NMOFs have been recently utilized as PAI contrast agents in
several studies due to their attractive characteristics such as
high porosity, tunable pore size, abundant metal sites and
high-guest molecule loading capacity, which allow them to be
designed as efficient PA contrast imaging agents as well as
therapeutics by simultaneously delivering various drug molecules.
For example, Chen and co-workers reported the fabrication of
multifunctional MOF nanoparticles for PAI-guided chemo-/
photothermal simultaneous tumour therapy by using
MIL-100(Fe).20 The Fe MOF nanoparticles were efficiently loaded
with curcumin, as a chemotherapeutic agent, and coated with
polydopamine (PDA) to achieve photoacoustic contrast and photo-
thermal conversion properties, and enhance the colloidal
stability and biocompatibility of the nanoparticles in the systemic
circulation. The produced nanoparticles were further function-
alized by hyaluronic acid (HA), through the modification of the
nanoparticles with HA conjugated PDA, to specifically target CD44
overexpressing tumour cells. The results showed that the nano-
particles accumulated significantly at the tumour site and
achieved photoacoustic imaging-guided combinational chemo-/
photothermal therapy with high therapeutic efficacy (Fig. 17).
Yang et al. reported the synthesis of ZIF-8 derived carbon
nanoparticles (ZCNs) using a one-step procedure, to achieve
PAI-guided cancer phototherapy and to investigate the effects of
the nanoparticle size on phototherapy and PAI contrast ability.35
The ZCNs acted as photothermal agents and photosensitizers by
simultaneously generating heat and reactive oxygen species which
caused efficient tumour ablation upon NIR laser irradiation, as
monitored by in vivo PAI. Furthermore, the results showed that
the increase in the nanoparticle size provided enhanced photo-
therapy effects and PA signal intensity (Fig. 18).
Similarly, Zhang et al. demonstrated new nanosized metal–
organic particles constructed directly using an organic dye,
tetrahydroxyanthraquinone (THQ), as linker connected by
Cu(II) ions serving as dual-mode therapeutics for PAI-guided
photothermal/chemotherapy in the NIR II window (from 1000
to 1350 nm of the optical spectrum).160 After PEGylation, the
nanoparticles (termed Cu-THQNPs) achieved excellent biocom-
patibility and colloidal stability. Their strong absorption in the
NIR II window and photo-induced electron transfer (PET)
mechanism enabled Cu-THQNPs to act as excellent photothermal
agents with a high light-to-heat conversion efficiency (51.3%) at
1064 nm, and also as excellent photoacoustic contrast agents.
Moreover, the degradation of the nanoparticles by tumour specific
acidic cleavage of the coordination bonds caused the release of
Cu(II) into the tumour area, enhancing antitumour activity
through catalysing conversion of hydrogen peroxide (H2O2) to
hydroxyl radicals (OH). In another study, ZIF-8 nanoparticles
were combined with AuNRs to obtain PA contrast agents (AuNR@-
ZIF-8) with high PAI capacity and biocompatibility.161 AuNR@ZIF-
8 core–shell nanocomposites were successfully built through a
facile step-by-step synthesis method, which involves attaching
PVP to the surface of the AuNR core and subsequently growth
of ZIF-8 on the AuNR surface. The resulting AuNR@ZIF-8 nano-
particles demonstrated high NIR absorption, good photothermal
conversion and PAI efficiency owing to the AuNR core, and easy
modification of the MOF surface, as well as high biocompatibility.
Overall, MOFs are being widely investigated as highly pro-
mising imaging agents for a number of diverse techniques,
primarily as a consequence of their synthetic versatility and the
possibility of combining imaging with drug delivery. Imaging
functionality can be intrinsic structural components of the
MOF or guests bound within pores or on particle surface, and
can be incorporated during synthesis or postsynthetically,
while MOFs can easily be hybridised with a range of other
nanomaterials. It is this versatility that means multiple imaging
functionalities can also easily be installed in single particles,
leading to multimodal imaging agents.
3. MOFs as multimodal imaging agents
Integration of multiple imaging modalities within a single
material is a highly promising approach to overcome the
Fig. 17 (a) Schematic illustration for the construction and applications of
MIL-100(Fe) for photoacoustic imaging-guided chemo-/photothermal
combinational tumour therapy. (b) PA intensity of the nanoparticles at
different concentrations. (c) Corresponding in vitro PA images. (d) PA
images of HeLa tumour-bearing mice at different time points after
intravenous injection with the nanoparticles. Reproduced with
permission.20 Copyright (2018) American Chemical Society.
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limitations of existing imaging techniques and obtain imaging
agents with high stability, biocompatibility, enhanced
imaging sensitivity and resolution capacity. The structural
and compositional diversity of NMOFs, combined with the
wide range of potential functionalization and hybridisation
protocols available, means they are excellent candidates for
multimodal imaging, in some cases in combination with
therapeutic applications.
3.1. OI/MRI
Combination of optical and MR imaging features within MOF
nanoparticles is one of the most applied strategies to achieve
non-invasive bimodal imaging agents with superior contrast
capacity. Kundu et al. reported the application of two
porous gadolinium(III)-based MOFs, Gd–pDBI-1 and Gd–pDBI-
2 (pDBI = 1,4-bis(5-carboxy-1H-benzimidazole-2-yl)benzene) for
bimodal imaging (Fig. 19a).162 The change in metal precursor
from Gd(NO3)36H2O to Gd(OAc)36H2O induced the formation
of two different MOFs, Gd–pDBI-1 and Gd–pDBI-2, respectively
(Fig. 19b), where enhanced porosity was reflected in the higher
BET surface area for Gd–pDBI-2 (614 m2 g1) compared to the
negligible N2 adsorption by Gd–pDBI-1 (33 m
2 g1, Fig. 19c).
The images recorded by SEM exhibited uniformly shaped
spindle-like particles about 1 mm in length and 0.3 mm in
width at the centre of Gd–pDBI-2, whereas Gd–pDBI-1 displayed
extensively aggregated, 120 nm rod-shaped particles (Fig. 19a).
The fluorescent pDBI linker in the structure enabled the
application of the MOFs as fluorescent agents – Gd–pDBI-2
exhibited greater luminescence than Gd–pDBI-1 (Fig. 19d) –
while the Gd core led them to serve as MRI contrast agents.
Confocal microscopy images revealed the bright blue-coloured
fluorescence of Gd–pDBI-2 within the cytoplasm of the MCF-7
cells at an excitation wavelength of 405 nm in vitro (Fig. 19e–g).
Of the two MOFs, Gd–pDBI-2 exhibited higher longitudinal
relaxivity (r1) as an MRI contrast agent (Fig. 19h and i). In vivo
MR images conducted on a mouse model confirmed the MRI
capabilities of Gd–pDBI-2 particles, generating a partial white
contrast on the spleen, kidney, and liver of the animal by using
a 0.3 T clinical MRI scanner, as shown in Fig. 19j and k.
In another example, Gao et al. reported the synthesis of
multifunctional MOFs for fluorescence/magnetic resonance
dual-mode imaging and targeted drug delivery.44 In the study,
MIL-53(Fe)-NH2 NMOFs, which have attractive properties such
as well-defined pores and intense magnetism, were loaded with
the anticancer drug 5-FU and decorated with FA for tumour
targeting. The nanoparticles were further functionalized by
conjugation of a fluorescent reagent, 5-carboxylfluorescein
(5-FAM), and employed successfully as MR and optical imaging
agents with a satisfactory magnetic performance and strong
green fluorescence emission. In addition, the particles
achieved higher cellular uptake and inhibition of cell growth
in FA-positive MGC-803 cells compared with FA-negative
HASMC cells. The group alternatively showed in situ growth
of MOFs on the surface of other MOFs as a new strategy to
construct dual imaging materials combining MR and optical
imaging properties in the same entity.163 Rodlike Eu-MOFs of
formula [Eu(BTC)(H2O)]n, which emit red fluorescence, were
grown on the surface of spherical MIL-100(Fe) particles that
could act as MRI contrast agents, by a simple in situ growth
method. MIL-100(Fe) particles were suspended in a DMF/water
solution of Eu(NO)36H2O and sodium acetate at 60 1C for 72 h,
with growth of the Eu-MOF presumably a consequence of
partial dissolution at MIL-100(Fe) surfaces and release of BTC
linkers. The Fe-MOF/Eu-MOF heterostructures simultaneously
exhibited red fluorescence arising from the Eu-MOF, and
enhanced T2-weighted MR images from MIL-100(Fe) acting as a
contrast agent. The nanocomposites showed strong fluorescence
in HASMC human aortic smooth muscle cells and MGC-803
cancer cells, as well as in vivo in athymic nude mice. The
Fe-MOF/Eu-MOF heterostructures were further loaded with 5-FU
and employed as a therapeutic agent with strong cell growth
inhibitory effect in MGC-803 cells.
Li et al. reported the integration of rare-earth-doped UCNPs
with MOFs to obtain core–shell UCNP@MOF for luminescent/
magnetic dual-mode targeted imaging.164 The particles were
prepared by the combination of single NaYF4:Yb,Er UCNP core
particles with a MIL-101(Fe)-NH2 NMOF shell, followed by
conjugation of poly(ethylene glycol)-2-amino ethyl ether acetic
Fig. 18 (a) Schematic representation of the synthesis and applications of
ZIF-8-derived carbon nanoparticles (ZCNs) for PAI-guided photothermal/
photodynamic combined therapy. PA signal intensity of ZCNs in vitro at (b)
different excitation wavelengths, and (c) various concentrations. (d) PA
imaging of A549 tumour-bearing mice at different times after intravenous
injection with ZCNs. The images display the tumour region of the mice.
Reproduced with permission.35 Copyright (2018) American Chemical
Society.
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acid (NH2–PEG–COOH) and FA tumour targeting unit, which
yielded PEGylated core–shell UCNP@MIL-101(Fe)-NH2@PEG–
FA nanostructures. Luminescence from the UCNPs is clearly
visible (Fig. 20a) and the Fe-MOF acted as a T2-weighted MRI
contrast agent (Fig. 20b). In vitro studies (Fig. 20c) performed
on KB cells (FR-positive) and MCF-7 cells (FR-negative), and
in vivo studies conducted on KB-tumour bearing mice
(Fig. 20d–i), demonstrated that the core–shell nanostructures
can simultaneously function as tumour targeted dual-mode
UCL/MR imaging agents, providing high luminescence
intensity from the UCNP core, and T2-MRI properties as the
MIL-101(Fe)-NH2 shell achieves a distinct darkening effect,
therefore enabling sensitive imaging with low toxicity and high
uptake in FR-positive KB cells.
In addition to their T2-MR imaging properties, SPIONs have
also attracted great attention for their photothermal conversion
efficiency. Zhang et al. combined these characteristics with the
photodynamic therapy and fluorescence imaging abilities of a
porphyrin MOF structure by constructing core–shell magnetic
porphyrin MOF nanocomposites for fluorescence-MR dual-
modality imaging-guided photothermal and photodynamic
dual-therapy.45 The core–shell nanocomposites were fabricated
by the encapsulation of Fe3O4 nanoparticle clusters in a carbon
shell, and then in situ self-assembly of a porphyrin MOF
(PMOF), constructed from Zr ions and TCPP with the PCN-
223 structure, on the surface of these Fe3O4@C nanoparticles.
The Fe3O4@C nanoparticles served as T2-weighted MR imaging
and PTT agents, while the PMOF enabled simultaneous
fluorescence imaging and PDT in the nanocomposite structure.
The resulting Fe3O4@C@PMOF nanocomposites demonstrated
high biocompatibility and stability, and effective fluorescence
and MR dual-modality imaging with high accumulation in the
tumour site of tumour-bearing mice. The nanostructures also
achieved effective photothermal and photodynamic therapy
of tumours without damaging normal tissues through the
controllable and local irradiation of the laser.
3.2. MRI/CT
Boyes and co-workers showed utilization of NMOFs as MR and
CT bimodal imaging agents by combining [Gd(BDC)1.5(H2O)2]n
nanorods, constructed from Gd(III) magnetic centres connected
by BDC linkers, and CTAB to prevent the aggregation of the
nanoparticles, with Au NPs via poly(acrylic acid) (PAA) bridges.
The highly stable Gd-MOF–PAA–Au nanocomposites showed
excellent MRI contrast with higher longitudinal relaxivity than
the clinically used MRI positive contrast agent Magnevist
through Gd(III) in the structure, and strong CT contrast through
Au NPs providing a source of high-Z elements. The composites,
however, were not tested towards any biological materials.165
3.3. MRI/PAI
Chen et al. described a facile approach to synthesize polypyrrole
(PPy) composite materials (PPy@MOFs), where a PPY core was
surrounded by a MIL-100(Fe) shell loaded with DOX, for
magnetic resonance/photoacoustic dual-mode imaging
combined with chemo-photothermal cancer therapy.166 PPy
NPs are well known for their high photothermal conversion
efficiency that allows efficient photothermal cancer therapy,
Fig. 19 (a) Schematic illustration of the synthesis of Gd–pDBI-1 and Gd–pDBI-2 from the luminescent linker pDBI under different reaction conditions
and their applications for simultaneous fluorescence and MR imaging. Left panel displays SEM (top) and TEM (bottom) images of Gd–pDBI-1; right panel
displays SEM (top) and TEM (bottom) images of Gd–pDBI-2. (b) PXRD patterns, (c) N2 adsorption isotherms, and (d) PL spectra of Gd–pDBI-1 and
Gd–pDBI-2; inset represents aqueous dispersion of Gd–pDBI-2 under visible light (white), 365 nm UV light (blue), and 254 nm UV light (bluish green).
Confocal microscopic images of MCF-7 cells incubated with Gd–pDBI-2: (e) bright-field, (f) merged, and (g) fluorescence image (lex = 405 nm).
Scale bars 20 mm. (h) T1-Weighted phantom image of Gd–pDBI-2 at different Gd(III) concentrations (1: 12.5 mg mL
1, 2: 25 mg mL1, 3: 50 mg mL1, 4:
100 mg mL1, 5: 200 mg mL1, 6: 300 mg mL1). (i) Comparison of longitudinal relaxivity (r1) of Gd–pDBI-1 and Gd–pDBI-2. In vivo MR images of (j) control
mouse and (k) mouse injected with Gd–pDBI-2. Reproduced with permission.162 Copyright (2016) Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
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and strong optical contrast for PAI.167–170 To obtain PPy@
MOFs, pyrrole was reacted with PVP and FeCl3 in deionized
water to generate the PPy core, where PVP was utilized as a
stabilizing agent and FeCl3 as a catalyst. Then, trimesic acid
was reacted with Fe(III) ions on the PPy surface, which act as
reactive sites, for the construction of PPy@MIL-100(Fe), and
finally the nanocomposites were loaded with DOX. PPy@MOFs
exhibited good biocompatibility and dual-mode PA and MR
imaging, as well as excellent photothermal conversion efficiency
(B40%) and NIR/pH-triggered release of DOX, resulting in
a synergistic chemo-photothermal therapy of HepG2 human
hepatocellular carcinoma cells.
3.4. OI/MRI/PAI
MOFs have also been employed as contrast agents for triple-
modality OI/MRI/PAI, especially for early diagnosis of tumours.
For example, Cai et al. reported NMOF-based multimodal
imaging guided photothermal cancer therapy.43 MIL-100(Fe),
as a T2-weighted MRI agent, was combined with a photo-
responsive NIR emitting organic dye indocyanine green (ICG),
after conjugation of the MOFs with hyaluronic acid (HA). The
produced nanoparticles (MOF@HA@ICG NPs, Fig. 21a) showed
high loading content of ICG (40%), and strong NIR emission
intensity and photostability. The in vitro (Fig. 21b–e) and in vivo
(Fig. 21f–j) imaging and photothermal toxicity studies exhibited
enhanced cellular uptake and tumour accumulation of the
HA-functionalized nanoparticles in CD44-positive MCF-7 cells
and MCF-7 tumour-bearing mice, providing an effective photo-
thermal toxicity, as well as strong fluorescence, photoacoustic,
and magnetic resonance multi-modal imaging capacities
compared to MOF@ICG NPs (non-HA-targeted) and free ICG.
Similarly, Yang et al. showed the synthesis of MIL-53(Fe)
loaded with a NIR cyanine dye (cypate), which can interact with
Fe(III) to construct precursor complexes, for near-infrared
fluorescence (NIRF), MR and PA imaging guided PTT/PDT
in vivo.171 The cyanine dye in the composition provided NIRF
and PA imaging abilities, and acted jointly as a PTT and PDT
agent by transforming NIR laser to heat and generating ROS
under NIR irradiation, respectively, while MIL-53(Fe) enabled
MR imaging. Moreover, incorporation of cypate molecules into
the structure increased the extent of defects in the MOF
nanoparticles, which enhanced the aqueous solubility and
bioavailability of cypate. Further modification of the particles
with transferrin, which has high binding affinity for the
transferrin receptors overexpressed on cancer cells, improved
internalization of the nanoparticles in A549 cells and in tumour
regions of A549 tumour-bearing mice with higher NIRF and
PA intensity, and more effective tumour ablation was
observed compared to untargeted nanoparticles upon a low
power laser.
Fig. 20 (a) Upconversion emission spectra of UCNP@MIL-101(Fe)-NH2@PEG–FA nanostructures (inset shows UCNP@MIL-101(Fe)-NH2@PEG–FA
dispersed in water under 980 nm diode excitation). (b) Relaxation rate r2 (1/T2) versus concentrations of UCNP@MIL-101(Fe)-NH2@PEG–FA at room
temperature measured by 3T MRI scanner (inset shows T2-weighted MR images of the nanostructures with various concentrations). (c) CLSM images of
KB (top) and MCF-7 (bottom) cells incubated with UCNP@MIL-101(Fe)-NH2@PEG-FA: (i) bright field, (ii) green channel images collected at 500–560 nm,
(iii) cell nucleus stained with Hoechst 33342 (blue fluorescence), and (iv) merged images. Dual-modal UCL/MR in vivo imaging of KB tumour-bearing
mice and their dissected organs at 24 h post-injection of (d) UCNP@MIL-101(Fe)-NH2@PEG–FA (UMP-FA, targeted) and (e) UCNP@MIL-101(Fe)-
NH2@PEG (UMP, without FA, non-targeted). (1) Heart; (2) kidney; (3) lung; (4) liver; (5) spleen; (6) KB tumour. T2-MRI images of KB tumour-bearing mice at
24 h after intravenous injection with (f) UCNP@MIL-101(Fe)-NH2@PEG–FA and (g) UCNP@MIL-101(Fe)-NH2@PEG. (h) Corresponding biodistributions of
the two samples. (i) Biodistribution of UCNP@MIL-101(Fe)-NH2@PEG after 0.5 h, 12 h, 24 h, 7 d, and 30 d following intravenous injection. Reproduced
with permission.164 Copyright (2015) Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
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3.5. MRI/CT/PAI
MOF nanoparticles have also been used as triple-modality
MRI/CT/PAI contrast agents by fabricating Au@MIL-88A(Fe)
nanostructures via controllable growth of a MIL-88A(Fe) shell
layer on the surface of AuNRs.172 The core–shell Au@MIL-88(Fe)
nanocomposites were further modified by poly(ethylene glycol)–
carboxylic acid (PEG–COOH) for higher colloidal stability in vivo.
The AuNR core in the structure provided CT enhancement and
PAI optical properties simultaneously, while MIL-88(Fe) served
as T2-weighted MRI contrast agent. The prepared nanostructures
showed low toxicity, and enabled high spatial resolution and
effective contrast during in vivo MRI, CT and PAI imaging of
glioma. In another study, Yang et al. showed the construction of
core–shell and co-doped Mn/Hf-IR825@PDA–PEG NMOPs
(NMOP-PEG) through a post-synthesis cation exchange method,
and described their application as MRI and PAI contrast agents
for bimodal imaging, and as radiosensitizers and photothermal
agents for synergistic thermo-radiotherapy.159 The particles
were produced by mixing the NMOPs (nanoscale metal–organic
particles) containing Mn(II) and IR825, a NIR dye, with Hf(IV),
and coating with polydopamine (PDA) and further conjugation
with PEG. The Mn(II) ions served as a contrast agent for
T1-weighted MR imaging, IR825 provided strong PA contrast
and a photothermal effect due to high NIR absorption, Hf(IV)
enabled the utilization of the particles as CT contrast agents and
for radiation therapy with strong X-ray absorbance, and the
further coatings by PDA and PEG endowed them with excellent
colloidal stability. The as-synthesized Mn/Hf-IR825@PDA–PEG
NMOPs showed efficient tumour retention ability after intravenous
injection in a mouse tumour model, which was confirmed by
MR/CT and PA images. Additionally, they demonstrated efficient
tumour killing efficacy by synergistic PTT and radiation therapy
(RT) treatment, which is attributed to the increased oxygenation
in the tumour region induced by PTT that repress tumour
hypoxia-related RT resistance, and radio-sensitization induced by
Hf. Furthermore, the particles were almost completely excreted
from the mouse body without causing any dark toxicity within a
month, showing them to be biodegradable and multifunctional
nanoplatforms for highly integrated clinical functions.
4. Conclusions and perspectives
In this review, we have highlighted and discussed the use of
MOFs and their composites as promising imaging agents for
various imaging modalities in clinical applications. Table 1
summarizes the applications of selected NMOFs as bioimaging
agents based on all imaging strategies and examples explained
above. For bioimaging, MOFs offer a variety of advantages such
as tunable porosity, controlled structure, synthetic versatilities,
diverse sizes and morphologies, high surface area, and easy
functionalization, which allows one to endow them with multiple
functionalities and properties. The wide-ranging choice of both
metal ions as coordination centres and organic ligands as linkers
further contribute to their compositional and structural
diversities. Their porous structures and high surface area allow
them to be simultaneously loaded with a wide variety of
therapeutic and imaging structures in large amounts, creating
MOF-based multimodal imaging-guided theranostic systems. The
tunable surface chemistry provides a facile route to modification
with various molecules to enhance their biocompatibility, stability
in physiological media, and/or the ability to targeting to a specific
region in the body. Biodegradability of NMOFs, combined with
rapid excretion and short-term body retention, provide a potential
pathway to their safe utilization for in vivo applications.
Beside being conjugated or loaded with active molecules,
NMOFs can also be directly constructed from various intrinsically
active metal ions or linkers. The use of certain inorganic metal
ions with imaging contrast abilities, e.g. Fe(III), Mn(II), Gd(III) and
Fig. 21 (a) Schematic illustration of the synthesis of MIL-100(Fe) NPs and their functionalization by HA conjugation and ICG loading. Imaging of MCF-7
cells in vitro: (b) PA images with (c) associated PA intensities for free ICQ, ICQ@MIL-100(Fe), and ICQ@HA@MIL-100(Fe), (d) fluorescence images and (e)
T2-weighted MR images of MCF-7 cells after incubation with ICQ@HA@MIL-100(Fe). Imaging of MCF-7 tumour-bearing mice in vivo: (f) fluorescence
images of mice injected with free ICQ, ICQ@MIL-100(Fe), and ICQ@HA@MIL-100(Fe) solutions, (g) corresponding ex vivo fluorescence images, (h)
fluorescence intensities of the organs and tumours, (i) in vivo PA and (j) T2-weighted MR images after MOF@HA@ICG treatment. Reproduced with
permission.43 Copyright (2016) American Chemical Society.
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Hf(IV), enables the construction of MOFs as contrast agents for OI,
MRI, CT, PET or PAI. Additionally, by using organic linkers with
imaging capabilities, such as luminescent porphyrin derivatives,
simultaneous imaging and therapy can be achieved. However,
there are still many important limitations and challenges
that need to be optimized for potential clinical applications of
MOFs as imaging contrast agents. Firstly, a systematic in vivo
toxicity evaluation, considering the accumulation, retention, and
metabolism of any residuals, is essential. This would also require
that any MOF proposed as an imaging device could be synthesised
with highly reproducible physical properties such as particle size,
morphology, and surface chemistry; precision manufacture at this
level is not trivial. Secondly, the poor solubility and colloidal
stability of MOFs in body fluids significantly limit their in vivo
bioimaging applications. For instance, many Zn-carboxylate MOFs
exhibit low stability in aqueous conditions due to the labile Zn





strategy Further applications Ref.
RsCnMOF-801, R6GCnUiO-67 Resorufin,
rhodamine-6G
— OI Liver cell targeting via galactosylation 18
MIL-53(Al)-NH2 RhB TCH, 5-FU OI Drug loading and release 29
RhB/ZIF-90 RhB — OI Mitochondrial ATP imaging 81
MIL-101(Fe) Br-BODIPY ESCP OI Drug loading and release 59
Zr-based MOFs Calcein a-Cyano-4-
hydroxycinnamic acid
OI Drug delivery, endocytosis 64
cal-TPP@(DCA5-UiO-66) Calcein DCA, TPP OI Mitochondria-targeted drug delivery 69
AuNR@MOFs@CPT TCPP CPT, Au NRs OI PDT/PTT/chemotherapy 80
NH2-MIL-101(Fe) Chlorine e6 CPT OI PDT/chemotherapy, tumour targeting via
FA, intracellular CaB targeting via CaB
substrate
91
DOX@Mi-UiO-68-FA DOX DOX OI Tumour targeting and therapy 66
FA@Eu:TMU-62-NH2 Eu 5-FU OI pH-Responsive targeted drug delivery 103
NaLnF4@MOF-Ln Ln = Y, Tm, Yb, Eu DOX OI (dual-mode
luminescence)
pH-Responsive drug delivery 105
ZGGO@ZIF-8-DOX ZGGO PLNPs DOX OI (persistent
luminescence)
pH-Responsive drug delivery 74
UCNP@ZIF-8/FA NaYF4:Yb(III),
Er(III)
5-FU OI (UCL) pH-Responsive targeted drug delivery 76






Gd-Based MOFs Gd(III) Eu(III), Tb(III) T1-Weighted
MRI
Luminescence imaging 28
Eu,Gd-NMOF@SiO2 Gd(III) Eu(III) T1- and T2-
weighted MRI
Luminescence imaging, tumour target-
ing via c(RGDyK)
19
Mn-IR825@PDA–PEG Mn(II) IR825 T1-Weighted
MRI
Photothermal therapy 141
Mn- and Gd-based MOFs Gd(III), Mn(II) — T1-Weighted
MRI
— 142
Iron(III) carboxylate MOFs (MIL-53,








DOX@ZIF-HA Fe(III) DOX T1-Weighted
MRI
Prostate cancer targeting via HA,
chemotherapy
144
Fe3O4@UiO-66 Fe3O4 DOX T2-Weighted
MRI
Chemotherapy 136
Fe3O4@IRMOF-3/FA Fe3O4 PTX, RITC T2-Weighted
MRI
Chemotherapy, fluorescence imaging 145
UiO-PDT BODIPY — CT — 33
89Zr–UiO-66/Py-PGA–PEG-F3 89Zr(IV) DOX, Py–PGA–PEG PET Tumour targeting via F3 peptide,
chemotherapy, fluorescence imaging
34
HA–PDA coated MIL-100(Fe) Fe(III) Curcumin PAI Chemotherapy, PTT, cancer targeting
via HA
20
ZIF-8-derived carbon nanoparticles Carbon PAI PDT, PTT 35
Gd–pDBI-1 and Gd–pDBI-2 Gd(III)/pDBI — T1-Weighted
MRI/OI
— 162
MIL-53(Fe)-NH2-FA-5-FAM/5-FU Fe(III)/5-FAM 5-FU T2-Weighted
MRI/OI
Tumour targeting via FA, chemotherapy 44





MOF@HA@ICG NPs Fe(III)/ICG — T2-Weighted
MRI/OI/PAI
PTT, tumour targeting via HA 43
Mn/Hf-IR825@PDA-PEG Mn(II)/IR825/Hf(IV) — T1-Weighted
MRI/PAI/CT
Thermo-radiotherapy 159
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carboxylate coordination. On the other hand, Zr-based MOFs,
which are typically chemically inert, have high affinity towards
phosphate ions found in culture medium and phosphate-buffered
saline.173 As such, the degradation mechanism and biostability of
currently available MOFs requires further studies. However, these
problems can potentially be solved by selecting low-toxicity metal
ions and organic linkers, and by appropriate functionalization
and/or coating of MOFs. Their synthetic, compositional, and
functional diversities mean that highly complex systems can be
assembled relatively easily, and so it is expected that they will play
a significant role in the biomedical field in the near future.
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